Baxter International Inc. (BAX)
Deerfield, IL, US
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Based on only 1 article — low confidence
| Target company | Date | Filing |
|---|---|---|
| FUSION | 2002-03-18 | View |
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1972-09-14 | — | Active |
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.56% | +2.16% | +2.22% | -6.31% | -6.26% | -8.27% | -45.01% | -58.72% | -78.90% | -61.58% | +1,188.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 12 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
27.00
+19.6%
|
| Last Quarter | 7 |
21.00
-7.0%
|
| Last Year | 15 |
22.80
+1.0%
|
| All Time | 35 |
48.40
+114.4%
|
-
Revenue growth Medical - Instruments & Supplies: +7.9%+5.7% Q1'26: +2.9% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-37.8% Q1'26: -112.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-4.9% Q1'26: +2.8% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-1.9% Q1'26: +2.4% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%-1.5% Q1'26: +1.9% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.6% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×13.06× Q1'26: 7.99× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 8 EPS Ana. |
Dec 2027 11 Rev. Ana. 9 EPS Ana. |
Dec 2028 8 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.56B
est: 12.40B (+1.3%)
|
12.84B
est: 12.65B (+1.5%)
|
13.89B
est: 13.53B (+2.7%)
|
13.94B
est: 14.12B (-1.3%)
|
9.41B
est: 14.81B (-36.4%)
|
10.72B
est: 10.29B (+4.2%)
|
9.97B
est: 9.91B (+0.6%)
|
10.16B
est: 10.17B (-0.1%)
|
10.58B
est: 10.56B (+0.3%)
|
11.10B
est: 11.08B (+0.1%)
|
11.36B
est: 11.36B (+0.0%)
|
11.67B
est: 11.58B (+0.8%)
|
12.15B
est: 12.57B (-3.4%)
|
10.06B
est: 15.00B (-32.9%)
|
10.36B
est: 15.00B (-30.9%)
|
10.64B
est: 10.56B (+0.8%)
|
11.24B
est: 11.08B (+1.5%)
|
11.36B
11.32B – 11.40B
+2.5% YoY
|
11.59B
11.46B – 11.73B
+2.0% YoY
|
11.90B
11.88B – 11.91B
+2.7% YoY
|
| EBITDA |
3.49B
est: 3.44B (+1.3%)
|
2.69B
est: 2.63B (+2.2%)
|
3.57B
est: 3.43B (+4.0%)
|
3.66B
est: 3.70B (-0.9%)
|
1.17B
est: 3.49B (-66.6%)
|
1.45B
est: 4.02B (-64.0%)
|
1.33B
est: 1.77B (-24.7%)
|
5.84B
est: 4.64B (+26.1%)
|
1.94B
est: 1.86B (+4.3%)
|
2.48B
est: 2.33B (+6.4%)
|
1.87B
est: 1.07B (+74.5%)
|
2.27B
est: 2.11B (+7.4%)
|
2.19B
est: 2.34B (-6.5%)
|
-1.76B
est: 2.57B (-168.5%)
|
1.73B
est: 1.04B (+67.4%)
|
1.12B
est: 729.32M (+53.0%)
|
766.00M
est: 765.69M (+0.0%)
|
784.96M
782.20M – 787.73M
+2.5% YoY
|
800.61M
791.61M – 810.29M
+2.0% YoY
|
821.83M
820.96M – 822.71M
+2.7% YoY
|
| EBIT |
2.85B
est: 2.84B (+0.5%)
|
2.01B
est: 2.09B (-4.1%)
|
2.90B
est: 2.86B (+1.5%)
|
2.95B
est: 2.81B (+5.1%)
|
530.00M
est: 2.64B (-79.9%)
|
657.00M
est: 2.71B (-75.8%)
|
574.00M
est: 1.01B (-43.1%)
|
5.04B
est: 595.84M (+746.4%)
|
1.19B
est: 1.13B (+4.5%)
|
1.71B
est: 1.45B (+17.7%)
|
1.08B
est: 78.18M (+1,282.7%)
|
1.45B
est: 1.51B (-4.1%)
|
1.32B
est: 1.56B (-15.3%)
|
-2.84B
est: 1.41B (-301.1%)
|
750.00M
est: -325.46M (+330.4%)
|
119.00M
est: -229.09M (+151.9%)
|
-215.00M
est: -240.52M (+10.6%)
|
-246.57M
-247.44M – -245.70M
-2.5% YoY
|
-251.49M
-254.53M – -248.66M
-2.0% YoY
|
-258.16M
-258.43M – -257.88M
-2.7% YoY
|
| Net Income |
2.21B
est: 2.17B (+1.4%)
|
1.42B
est: 1.39B (+2.3%)
|
2.22B
est: 2.16B (+3.1%)
|
2.33B
est: 2.31B (+0.5%)
|
2.01B
est: 1.99B (+1.2%)
|
2.50B
est: 2.41B (+3.7%)
|
968.00M
est: 821.07M (+17.9%)
|
4.97B
est: 3.91B (+26.9%)
|
602.00M
est: 642.47M (-6.3%)
|
1.55B
est: 1.48B (+4.7%)
|
1.00B
est: 1.74B (-42.5%)
|
1.10B
est: 1.02B (+7.9%)
|
1.28B
est: 1.17B (+9.9%)
|
-2.43B
est: 1.02B (-337.7%)
|
2.66B
est: -158.97M (+1,770.8%)
|
-649.00M
est: 942.82M (-168.8%)
|
-957.00M
est: 1.22B (-178.7%)
|
977.49M
949.27M – 1.01B
-19.6% YoY
|
1.02B
960.36M – 1.08B
+4.6% YoY
|
1.10B
1.02B – 1.18B
+7.6% YoY
|
| SGA |
2.73B
est: 2.69B (+1.3%)
|
2.91B
est: 2.86B (+1.5%)
|
3.15B
est: 3.07B (+2.7%)
|
3.28B
est: 3.31B (-0.8%)
|
3.08B
est: 4.43B (-30.4%)
|
3.32B
est: 5.81B (-42.9%)
|
3.09B
est: 2.91B (+6.4%)
|
2.73B
est: 2.24B (+21.8%)
|
2.63B
est: 2.34B (+12.4%)
|
2.62B
est: 2.34B (+12.1%)
|
2.54B
est: 2.99B (-15.3%)
|
2.47B
est: 2.37B (+4.3%)
|
2.85B
est: 2.65B (+7.2%)
|
3.10B
est: 3.52B (-12.0%)
|
2.95B
est: 4.09B (-27.8%)
|
2.97B
est: 2.88B (+3.1%)
|
2.89B
est: 3.02B (-4.4%)
|
3.10B
3.09B – 3.11B
+2.5% YoY
|
3.16B
3.12B – 3.20B
+2.0% YoY
|
3.24B
3.24B – 3.25B
+2.7% YoY
|
| EPS |
3.63
est: 3.70 (-1.9%)
|
2.41
est: 3.86 (-37.6%)
|
3.91
est: 4.09 (-4.4%)
|
4.22
est: 4.49 (-6.0%)
|
3.70
est: 4.56 (-18.9%)
|
4.61
est: 4.76 (-3.2%)
|
1.78
est: 1.26 (+41.6%)
|
9.09
est: 1.91 (+376.6%)
|
1.11
est: 2.43 (-54.3%)
|
3.04
est: 3.00 (+1.3%)
|
1.97
est: 3.41 (-42.3%)
|
2.17
est: 3.06 (-29.0%)
|
2.56
est: 3.60 (-28.8%)
|
-4.83
est: 3.56 (-235.7%)
|
5.25
est: -0.31 (+1,797.1%)
|
-1.27
est: 1.84 (-169.1%)
|
-1.75
est: 2.37 (-174.0%)
|
1.92
1.85 – 1.96
-18.8% YoY
|
1.99
1.87 – 2.11
+3.7% YoY
|
2.14
1.98 – 2.31
+7.6% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | Barclays | Overweight | Overweight | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 131.90M | 19.40% | 1.00 | — | 131.90M | — | CO | Delaware | 2016-02-12 | ↗ |
| 2 | Wellington Group Holdings LLP | 56.89M | 11.33% | — | 54.40M | — | — | HC | Delaware | 2022-03-10 | ↗ |
| 3 | Wellington Investment Advisors Holdings LLP | 56.89M | 11.33% | — | 54.40M | — | — | HC | Delaware | 2022-03-10 | ↗ |
| 4 | Wellington Management Group LLP | 56.89M | 11.33% | — | 54.40M | — | — | HC | Massachusetts | 2022-03-10 | ↗ |
| 5 | Wellington Management Company LLP | 52.33M | 10.42% | — | 51.79M | — | — | IA | Delaware | 2022-03-10 | ↗ |
| 6 | (1) BlackRock, Inc. | 40.11M | 8.00% | 35.25M | — | 40.11M | — | HC | Delaware | 2022-02-01 | ↗ |
| 7 | The Vanguard Group - 23-1945930 | 38.98M | 7.79% | — | 800.5K | 36.95M | 2.03M | IA | Pennsylvania For | 2022-02-09 | ↗ |
| 8 | Morgan Stanley | 28.50M | 5.70% | — | 25.97M | — | 13.00 | HC, CO | Delaware | 2022-02-09 | ↗ |
| 9 | 94-1441976 | 27.38M | 5.40% | 25.60M | — | 27.38M | — | IA | U.S.A. | 2024-02-13 | ↗ |
| 10 | Morgan Stanley Investment Management Limited | 26.04M | 5.20% | — | 23.54M | — | 13.00 | IA | Delaware | 2022-02-09 | ↗ |
| 11 | Daniel S. Loeb | 23.01M | 4.50% | — | 23.01M | — | 10.00 | IN | United States | 2019-05-17 | ↗ |
| 12 | Third Point LLC | 23.01M | 4.50% | — | 23.01M | — | 10.00 | OO | Delaware | 2019-05-17 | ↗ |
| 13 | 2. | 15.67M | 8.70% | — | — | — | 15.67M | CO | Delaware | 2015-05-01 | ↗ |
| 14 | Healthcare Corporation | 2.08M | 10.30% | — | 2.08M | — | 2.08M | CO | Delaware | 2022-02-14 | ↗ |
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 84.78M +7.0M (+8.9%) | 1.62B -151.9M (-8.6%) | 16.49% +1.324 pp | 0.03% -0.004 pp | USD34.28 -44.3% | 6 qtrs — |
| 2 | PZENA INVESTMENT MANAGEMENT LLC | 70.05M +12.7M (+22.1%) | 1.34B +31.9M (+2.4%) | 13.63% +2.441 pp | 4.01% -0.216 pp | USD29.74 -35.7% | 10 qtrs — |
| 3 | VANGUARD GROUP INC | 62.64M +109.5K (+0.2%) | 1.20B -226.8M (-15.9%) | 12.19% -0.002 pp | 0.02% -0.004 pp | USD44.40 -57.0% | 84 qtrs — |
| 4 | DODGE & COX | 57.00M -396.4K (-0.7%) | 1.09B -217.6M (-16.7%) | 11.11% -0.077 pp | 0.59% -0.117 pp | USD35.71 -46.5% | 10 qtrs — |
| 5 | FMR LLC | 34.81M +20.2M (+138.9%) | 665.25M +333.5M (+100.5%) | 6.79% +3.945 pp | 0.03% +0.017 pp | USD22.04 -13.3% | 70 qtrs — |
| 6 | STATE STREET CORP | 22.54M +542.0K (+2.5%) | 430.95M -73.6M (-14.6%) | 4.39% +0.097 pp | 0.01% -0.003 pp | USD44.46 -57.0% | 51 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 13.51M +972.9K (+7.8%) | 257.17M -27.1M (-9.5%) | 2.63% +0.185 pp | 0.02% -0.002 pp | USD48.10 -60.3% | 78 qtrs — |
| 8 | INVESCO LTD. | 11.86M +3.2M (+36.3%) | 226.67M +28.5M (+14.4%) | 2.31% +0.611 pp | 0.03% +0.004 pp | USD36.40 -47.5% | 57 qtrs — |
| 9 | GREENHAVEN ASSOCIATES INC | 10.69M +4.4M (+70.0%) | 204.35M +61.2M (+42.7%) | 2.08% +0.855 pp | 3.31% +1.134 pp | USD21.26 -10.1% | 2 qtrs — |
| 10 | UBS GROUP AG | 10.67M +6.8M (+174.0%) | 203.84M +115.2M (+130.0%) | 2.08% +1.317 pp | 0.03% +0.019 pp | USD24.39 -21.6% | 45 qtrs — |
| 11 | MORGAN STANLEY | 8.62M +2.1M (+32.0%) | 164.65M +16.1M (+10.8%) | 1.68% +0.404 pp | 0.01% +0.001 pp | USD44.13 -56.7% | 51 qtrs — |
| 12 | HARRIS ASSOCIATES L P | 8.45M -26.6K (-0.3%) | 161.40M -31.5M (-16.3%) | 1.64% -0.008 pp | 0.20% -0.105 pp | USD39.27 -51.3% | 40 qtrs — |
| 13 | STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 6.23M +— (+0.0%) | 118.96M -22.8M (-16.1%) | 1.21% -0.002 pp | 0.09% -0.025 pp | USD17.56 +8.8% | 108 qtrs — |
| 14 | NORGES BANK | 6.19M +6.2M (+100.0%) | 118.32M +118.3M (+100.0%) | 1.20% +1.205 pp | 0.01% +0.013 pp | USD19.11 +0.0% | 1 qtrs NEW |
| 15 | LAZARD ASSET MANAGEMENT LLC | 6.19M +319.5K (+5.4%) | 118.25M -15.4M (-11.5%) | 1.20% +0.060 pp | 0.20% +0.021 pp | USD31.09 -38.5% | 51 qtrs — |
| 16 | DIMENSIONAL FUND ADVISORS LP | 5.77M +2.3M (+65.7%) | 110.29M +31.0M (+39.1%) | 1.12% +0.444 pp | 0.02% +0.006 pp | USD35.43 -46.1% | 51 qtrs — |
| 17 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 5.31M +267.0K (+5.3%) | 101.51M -13.4M (-11.6%) | 1.04% +0.052 pp | 0.02% -0.003 pp | USD42.44 -55.0% | 100 qtrs — |
| 18 | EQUITY INVESTMENT CORP | 4.90M +237.2K (+5.1%) | 93.58M -12.5M (-11.8%) | 0.95% +0.044 pp | 1.89% -0.333 pp | USD28.36 -32.6% | 5 qtrs — |
| 19 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 4.76M -256.1K (-5.1%) | 90.92M -23.2M (-20.4%) | 0.93% -0.052 pp | 0.14% -0.026 pp | USD39.71 -51.9% | 12 qtrs — |
| 20 | NORTHERN TRUST CORP | 4.67M -8.3K (-0.2%) | 89.31M -17.3M (-16.2%) | 0.91% -0.002 pp | 0.01% -0.002 pp | USD42.55 -55.1% | 51 qtrs — |
| 21 | LSV ASSET MANAGEMENT | 4.31M -214.8K (-4.7%) | 82.32M -20.7M (-20.1%) | 0.84% -0.044 pp | 0.18% -0.048 pp | USD34.46 -44.5% | 7 qtrs — |
| 22 | BANK OF AMERICA CORP /DE/ | 4.27M -980.4K (-18.7%) | 81.66M -38.0M (-31.7%) | 0.83% -0.193 pp | 0.01% -0.002 pp | USD36.79 -48.1% | 52 qtrs — |
| 23 | RUSSELL INVESTMENTS GROUP, LTD. | 3.41M +894.8K (+35.6%) | 65.22M +8.0M (+13.9%) | 0.66% +0.174 pp | 0.07% +0.006 pp | USD31.42 -39.2% | 37 qtrs — |
| 24 | THOMPSON SIEGEL & WALMSLEY LLC | 3.33M +356.6K (+12.0%) | 63.60M -4.1M (-6.0%) | 0.65% +0.068 pp | 1.07% -0.026 pp | USD28.58 -33.1% | 84 qtrs — |
| 25 | NORDEA INVESTMENT MANAGEMENT AB | 3.10M -1.1M (-25.3%) | 59.73M -32.7M (-35.4%) | 0.60% -0.206 pp | 0.05% -0.030 pp | USD36.99 -48.3% | 88 qtrs — |
| 26 | BANK OF NEW YORK MELLON CORP | 3.02M -1.3M (-29.8%) | 57.70M -40.2M (-41.1%) | 0.59% -0.251 pp | 0.01% -0.009 pp | USD37.57 -49.1% | 66 qtrs — |
| 27 | GOLDMAN SACHS GROUP INC | 2.90M +1.2M (+68.5%) | 55.51M +16.3M (+41.4%) | 0.57% +0.229 pp | 0.01% +0.002 pp | USD32.29 -40.8% | 73 qtrs — |
| 28 | UBS ASSET MANAGEMENT AMERICAS INC | 2.89M -86.7K (-2.9%) | 55.29M -12.6M (-18.5%) | 0.56% -0.018 pp | 0.01% -0.003 pp | USD46.07 -58.5% | 90 qtrs — |
| 29 | DEUTSCHE BANK AG\ | 2.68M +479.8K (+21.9%) | 51.12M +1.1M (+2.3%) | 0.52% +0.093 pp | 0.02% 0.000 pp | USD38.71 -50.6% | 50 qtrs — |
| 30 | LEGAL & GENERAL GROUP PLC | 2.43M -684.0K (-21.9%) | 46.53M -24.5M (-34.5%) | 0.47% -0.134 pp | 0.01% -0.006 pp | USD52.37 -63.5% | 75 qtrs — |
| 31 | JPMORGAN CHASE & CO | 2.40M -487.9K (-16.9%) | 45.79M -19.9M (-30.3%) | 0.47% -0.096 pp | 0.00% -0.001 pp | USD48.64 -60.7% | 51 qtrs — |
| 32 | FIL LTD | 2.09M +346.3K (+19.8%) | 40.01M +223.0K (+0.6%) | 0.41% +0.068 pp | 0.03% -0.001 pp | USD31.13 -38.6% | 31 qtrs — |
| 33 | PALE FIRE CAPITAL SE | 2.07M +2.1M (+100.0%) | 39.63M +39.6M (+100.0%) | 0.40% +0.404 pp | 2.66% +2.660 pp | USD19.11 +0.0% | 1 qtrs NEW |
| 34 | EDMOND DE ROTHSCHILD HOLDING S.A. | 1.77M +124.0K (+7.5%) | 33.79M -3.6M (-9.7%) | 0.34% +0.024 pp | 0.48% -0.099 pp | USD39.41 -51.5% | 43 qtrs — |
| 35 | AMUNDI | 1.75M +643.5K (+58.0%) | 33.52M +7.8M (+30.4%) | 0.34% +0.125 pp | 0.01% +0.001 pp | USD39.65 -51.8% | 19 qtrs — |
| 36 | SG AMERICAS SECURITIES, LLC | 1.73M +1.4M (+477.6%) | 32.97M +26.2M (+384.8%) | 0.34% +0.277 pp | 0.04% +0.019 pp | USD19.83 -3.6% | 51 qtrs — |
| 37 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.71M +1.7M (+100.0%) | 32.68M +32.7M (+100.0%) | 0.33% +0.333 pp | 0.11% +0.115 pp | USD19.11 +0.0% | 1 qtrs NEW |
| 38 | CALLODINE CAPITAL MANAGEMENT, LP | 1.61M -144.8K (-8.2%) | 30.79M -9.2M (-23.0%) | 0.31% -0.028 pp | 2.47% -1.030 pp | USD31.99 -40.3% | 10 qtrs — |
| 39 | RAYMOND JAMES FINANCIAL INC | 1.50M +71.9K (+5.0%) | 28.62M -3.8M (-11.8%) | 0.29% +0.014 pp | 0.01% -0.002 pp | USD27.94 -31.6% | 5 qtrs — |
| 40 | BARCLAYS PLC | 1.43M +373.3K (+35.4%) | 27.26M -12.7M (-31.8%) | 0.28% +0.072 pp | 0.01% -0.004 pp | USD38.98 -51.0% | 51 qtrs — |
| 41 | SWISS NATIONAL BANK | 1.34M -138.0K (-9.3%) | 25.63M -8.0M (-23.9%) | 0.26% -0.027 pp | 0.02% -0.004 pp | USD55.01 -65.3% | 51 qtrs — |
| 42 | NATIXIS ADVISORS, L.P. | 1.28M -206.4K (-13.9%) | 24.50M -9.4M (-27.7%) | 0.25% -0.041 pp | 0.03% -0.015 pp | USD34.96 -45.3% | 57 qtrs — |
| 43 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 1.28M -13.1K (-1.0%) | 24.45M -5.0M (-16.9%) | 0.25% -0.003 pp | 0.01% -0.003 pp | USD52.17 -63.4% | 59 qtrs — |
| 44 | BANK OF MONTREAL /CAN/ | 1.17M +309.0K (+35.9%) | 22.34M +2.8M (+14.1%) | 0.23% +0.060 pp | 0.01% +0.000 pp | USD48.46 -60.6% | 51 qtrs — |
| 45 | CITADEL ADVISORS LLC | 1.16M -735.9K (-38.9%) | 22.10M -21.0M (-48.7%) | 0.23% -0.144 pp | 0.00% -0.003 pp | USD24.34 -21.5% | 52 qtrs — |
| 46 | RHUMBLINE ADVISERS | 1.15M +10.5K (+0.9%) | 21.99M -4.0M (-15.3%) | 0.22% +0.002 pp | 0.02% -0.003 pp | USD43.37 -55.9% | 55 qtrs — |
| 47 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 1.11M +120.1K (+12.1%) | 21.72M -908.1K (-4.0%) | 0.22% +0.023 pp | 0.01% -0.002 pp | USD40.97 -53.4% | 58 qtrs — |
| 48 | CITIGROUP INC | 1.05M +543.4K (+106.6%) | 20.13M +8.5M (+73.4%) | 0.21% +0.106 pp | 0.01% +0.004 pp | USD25.80 -25.9% | 108 qtrs — |
| 49 | AUTO-OWNERS INSURANCE CO | 1.05M +— (+0.0%) | 20.07M -3.8M (-16.1%) | 0.20% 0.000 pp | 0.42% -0.196 pp | USD30.19 -36.7% | 5 qtrs — |
| 50 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.03M -470.3K (-31.2%) | 19.78M -14.5M (-42.3%) | 0.20% -0.092 pp | 0.00% -0.002 pp | USD25.92 -26.3% | 51 qtrs — |
| 51 | NUVEEN, LLC | 984.6K -128.4K (-11.5%) | 18.82M -6.5M (-25.8%) | 0.19% -0.025 pp | 0.00% -0.002 pp | USD34.03 -43.8% | 4 qtrs — |
| 52 | ENVESTNET ASSET MANAGEMENT INC | 959.1K -47.2K (-4.7%) | 18.33M -4.6M (-20.0%) | 0.19% -0.010 pp | 0.01% -0.001 pp | USD42.19 -54.7% | 51 qtrs — |
| 53 | HSBC HOLDINGS PLC | 885.3K +34.3K (+4.0%) | 16.95M -2.4M (-12.2%) | 0.17% +0.006 pp | 0.01% -0.002 pp | USD41.94 -54.4% | 56 qtrs — |
| 54 | ROYAL BANK OF CANADA | 860.4K -3.1M (-78.2%) | 16.44M -73.5M (-81.7%) | 0.17% -0.602 pp | 0.00% -0.012 pp | USD31.72 -39.8% | 51 qtrs — |
| 55 | BNP PARIBAS ARBITRAGE, SNC | 838.1K +8.9K (+1.1%) | 16.02M -2.9M (-15.2%) | 0.16% +0.001 pp | 0.01% -0.003 pp | USD39.50 -51.6% | 51 qtrs — |
| 56 | ARGA INVESTMENT MANAGEMENT, LP | 819.0K +122.0 (+0.0%) | 15.65M -3.0M (-16.1%) | 0.16% 0.000 pp | 0.43% -0.068 pp | USD33.61 -43.1% | 8 qtrs — |
| 57 | PRICE T ROWE ASSOCIATES INC /MD/ | 761.4K -12.7M (-94.3%) | 14.55M -291.8M (-95.2%) | 0.15% -2.474 pp | 0.00% -0.031 pp | USD39.37 -51.5% | 75 qtrs — |
| 58 | SQUAREPOINT OPS LLC | 759.9K +427.5K (+128.6%) | 14.52M +7.0M (+91.9%) | 0.15% +0.083 pp | 0.02% +0.008 pp | USD21.85 -12.5% | 44 qtrs — |
| 59 | INVENOMIC CAPITAL MANAGEMENT LP | 746.7K +380.0K (+103.6%) | 14.27M +5.9M (+70.9%) | 0.15% +0.074 pp | 0.66% +0.260 pp | USD20.91 -8.6% | 2 qtrs — |
| 60 | WELLS FARGO & COMPANY/MN | 746.3K -142.2K (-16.0%) | 14.26M -6.0M (-29.5%) | 0.15% -0.028 pp | 0.00% -0.001 pp | USD48.64 -60.7% | 57 qtrs — |
| 61 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 699.0K -11.9K (-1.7%) | 13.36M -2.8M (-17.5%) | 0.14% -0.003 pp | 0.01% -0.002 pp | USD63.80 -70.0% | 57 qtrs — |
| 62 | NATIXIS | 641.9K +641.9K (+100.0%) | 12.27M +12.3M (+100.0%) | 0.13% +0.125 pp | 0.04% +0.044 pp | USD19.11 +0.0% | 1 qtrs NEW |
| 63 | ARNHOLD LLC | 629.3K +629.3K (+100.0%) | 12.03M +12.0M (+100.0%) | 0.12% +0.122 pp | 0.91% +0.912 pp | USD19.11 +0.0% | 1 qtrs NEW |
| 64 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 620.8K +339.7K (+120.8%) | 11.86M +5.5M (+85.3%) | 0.12% +0.066 pp | 0.03% +0.011 pp | USD20.87 -8.4% | 5 qtrs — |
| 65 | PARKWOOD LLC | 619.8K +619.8K (+100.0%) | 11.85M +11.8M (+100.0%) | 0.12% +0.121 pp | 0.92% +0.917 pp | USD19.11 +0.0% | 7 qtrs — |
| 66 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 609.6K -12.6K (-2.0%) | 11.65M -2.5M (-17.8%) | 0.12% -0.003 pp | 0.01% -0.003 pp | USD48.34 -60.5% | 52 qtrs — |
| 67 | AQR CAPITAL MANAGEMENT LLC | 603.3K +315.4K (+109.5%) | 11.53M +5.1M (+79.2%) | 0.12% +0.062 pp | 0.01% +0.002 pp | USD21.84 -12.5% | 85 qtrs — |
| 68 | MOORE CAPITAL MANAGEMENT, LP | 577.7K +115.2K (+24.9%) | 11.04M +508.2K (+4.8%) | 0.11% +0.022 pp | 0.16% +0.014 pp | USD22.04 -13.3% | 2 qtrs — |
| 69 | ALLIANCEBERNSTEIN L.P. | 575.5K -40.6K (-6.6%) | 11.00M -3.0M (-21.6%) | 0.11% -0.008 pp | 0.00% -0.001 pp | USD46.19 -58.6% | 61 qtrs — |
| 70 | PRINCIPAL FINANCIAL GROUP INC | 567.2K +14.2K (+2.6%) | 10.84M -1.8M (-13.9%) | 0.11% +0.003 pp | 0.01% -0.001 pp | USD44.72 -57.3% | 81 qtrs — |
| 71 | NATIONAL PENSION SERVICE | 537.2K +106.2K (+24.6%) | 10.27M +452.5K (+4.6%) | 0.10% +0.021 pp | 0.01% +0.000 pp | USD38.53 -50.4% | 46 qtrs — |
| 72 | CIBC ASSET MANAGEMENT INC | 517.0K +80.4K (+18.4%) | 9.88M -61.7K (-0.6%) | 0.10% +0.016 pp | 0.02% -0.005 pp | USD38.18 -49.9% | 89 qtrs — |
| 73 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 503.6K +199.3K (+65.5%) | 9.62M +2.7M (+38.9%) | 0.10% +0.039 pp | 0.08% +0.005 pp | USD23.47 -18.6% | 3 qtrs — |
| 74 | GABELLI FUNDS LLC | 495.0K -202.0K (-29.0%) | 9.46M -6.4M (-40.4%) | 0.10% -0.040 pp | 0.06% -0.043 pp | USD38.09 -49.8% | 64 qtrs — |
| 75 | FRONT STREET CAPITAL MANAGEMENT, INC. | 478.7K +220.2K (+85.2%) | 9.15M +3.3M (+55.4%) | 0.09% +0.043 pp | 1.30% +0.391 pp | USD21.09 -9.4% | 2 qtrs — |
| 76 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 469.7K -11.3K (-2.3%) | 8.98M -2.0M (-18.0%) | 0.09% -0.002 pp | 0.02% -0.003 pp | USD41.31 -53.7% | 51 qtrs — |
| 77 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 464.0K +146.5K (+46.1%) | 8.87M +1.6M (+22.6%) | 0.09% +0.028 pp | 0.01% +0.002 pp | USD27.39 -30.2% | 55 qtrs — |
| 78 | GENDELL JEFFREY L | 446.1K +446.1K (+100.0%) | 8.53M +8.5M (+100.0%) | 0.09% +0.087 pp | 0.15% +0.148 pp | USD19.11 +0.0% | 1 qtrs NEW |
| 79 | NEW YORK STATE COMMON RETIREMENT FUND | 441.5K -5.4K (-1.2%) | 8.44M -1.7M (-17.1%) | 0.09% -0.001 pp | 0.01% -0.002 pp | USD48.01 -60.2% | 103 qtrs — |
| 80 | OLSTEIN CAPITAL MANAGEMENT, L.P. | 417.0K +52.0K (+14.2%) | 7.97M -342.0K (-4.1%) | 0.08% +0.010 pp | 1.63% +0.065 pp | USD37.95 -49.6% | 35 qtrs — |
| 81 | SEI INVESTMENTS CO | 410.0K -174.3K (-29.8%) | 7.83M -5.5M (-41.1%) | 0.08% -0.034 pp | 0.01% -0.007 pp | USD47.48 -59.8% | 45 qtrs — |
| 82 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 397.0K +4.4K (+1.1%) | 7.59M -1.4M (-15.1%) | 0.08% +0.001 pp | 0.02% -0.004 pp | USD47.37 -59.7% | 57 qtrs — |
| 83 | GAMCO INVESTORS, INC. ET AL | 391.3K +35.3K (+9.9%) | 7.48M -628.2K (-7.8%) | 0.08% +0.007 pp | 0.07% -0.007 pp | USD29.48 -35.2% | 64 qtrs — |
| 84 | TOCQUEVILLE ASSET MANAGEMENT L.P. | 382.2K +382.2K (+100.0%) | 7.30M +7.3M (+100.0%) | 0.07% +0.074 pp | 0.11% +0.107 pp | USD19.11 +0.0% | 1 qtrs NEW |
| 85 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 381.7K +2.0K (+0.5%) | 7.29M -1.4M (-15.6%) | 0.07% +0.000 pp | 0.01% -0.001 pp | USD51.38 -62.8% | 108 qtrs — |
| 86 | SWEDBANK AB | 381.4K +100.9K (+36.0%) | 7.29M +901.8K (+14.1%) | 0.07% +0.020 pp | 0.01% +0.001 pp | USD35.22 -45.7% | 20 qtrs — |
| 87 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 376.4K +11.0 (+0.0%) | 7.19M -1.4M (-16.1%) | 0.07% 0.000 pp | 0.01% -0.003 pp | USD38.63 -50.5% | 51 qtrs — |
| 88 | SOUTH DAKOTA INVESTMENT COUNCIL | 366.7K +4.2K (+1.2%) | 7.01M -1.2M (-15.1%) | 0.07% +0.001 pp | 0.13% -0.027 pp | USD48.08 -60.3% | 14 qtrs — |
| 89 | ABRDN PLC | 365.9K -51.6K (-12.4%) | 6.99M -2.3M (-25.1%) | 0.07% -0.010 pp | 0.01% -0.004 pp | USD46.90 -59.3% | 34 qtrs — |
| 90 | VICTORY CAPITAL MANAGEMENT INC | 354.2K +209.8K (+145.3%) | 6.77M +3.5M (+105.8%) | 0.07% +0.041 pp | 0.00% +0.002 pp | USD33.10 -42.3% | 50 qtrs — |
| 91 | GREAT LAKES ADVISORS, LLC | 349.8K -40.6K (-10.4%) | 6.69M -2.2M (-24.8%) | 0.07% -0.008 pp | 0.05% -0.020 pp | USD49.56 -61.4% | 19 qtrs — |
| 92 | BECKER CAPITAL MANAGEMENT INC | 347.8K -67.9K (-16.3%) | 6.65M -2.9M (-30.3%) | 0.07% -0.013 pp | 0.19% -0.088 pp | USD37.97 -49.7% | 6 qtrs — |
| 93 | — | 344.6K +151.7K (+78.6%) | 6.59M +2.2M (+49.9%) | 0.07% +0.029 pp | 0.65% -0.029 pp | USD21.16 -9.7% | 2 qtrs — |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Wallace Steven P. | Officer | — | — | Stock Option (Right to Buy) | 25,862 | 20.37 | 526.8K | 0 | D | ↗ |
| 2026-04-01 | Teaff James | Officer | — | — | Stock Option (Right to Buy) | 3,436 | 66.31 | 227.8K | 0 | D | ↗ |
| 2026-04-01 | Foster Julie | Officer | — | — | Common Stock, $1 par value | 0 | 0.00 | — | 31,248 | D | ↗ |
| 2026-03-06 | Zielinski Anita A | Officer | F-InKind | D | Common Stock, $1 par value | 1,932 | 17.69 | 34.2K | 46,281 | D | ↗ |
| 2026-03-06 | Soriano Maria Cecilia | Officer | F-InKind | D | Common Stock, $1 par value | 2,848 | 17.69 | 50.4K | 75,045 | D | ↗ |
| 2026-03-06 | Rosenbloom David S. | Officer | F-InKind | D | Common Stock, $1 par value | 6,620 | 17.69 | 117.1K | 138,216 | D | ↗ |
| 2026-03-06 | Rasul Reazur | Officer | F-InKind | D | Common Stock, $1 par value | 12,674 | 17.69 | 224.2K | 125,557 | D | ↗ |
| 2026-03-06 | Grade Joel T. | Officer | F-InKind | D | Common Stock, $1 par value | 8,153 | 17.69 | 144.2K | 271,674 | D | ↗ |
| 2026-03-02 | Soriano Maria Cecilia | Officer | F-InKind | D | Common Stock, $1 par value | 1,852 | 19.69 | 36.5K | 77,894 | D | ↗ |
| 2026-03-02 | Rosenbloom David S. | Officer | F-InKind | D | Common Stock, $1 par value | 1,336 | 19.69 | 26.3K | 144,837 | D | ↗ |
| 2026-03-02 | Rasul Reazur | Officer | F-InKind | D | Common Stock, $1 par value | 1,614 | 19.69 | 31.8K | 138,231 | D | ↗ |
| 2026-02-27 | Zielinski Anita A | Officer | A-Award | A | Common Stock, $1 par value | 30,864 | 0.00 | — | 48,214 | D | ↗ |
| 2026-02-27 | Soriano Maria Cecilia | Officer | A-Award | A | Stock Option (Right to Buy) | 57,471 | 20.37 | 1.17M | 57,471 | D | ↗ |
| 2026-02-27 | Rosenbloom David S. | Officer | A-Award | A | Stock Option (Right to Buy) | 64,655 | 20.37 | 1.32M | 64,655 | D | ↗ |
| 2026-02-27 | Hider Andrew P. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 488,506 | 20.37 | 9.95M | 488,506 | D | ↗ |
| 2026-02-27 | Grade Joel T. | Officer | A-Award | A | Stock Option (Right to Buy) | 103,448 | 20.37 | 2.11M | 103,448 | D | ↗ |
| 2026-02-27 | Carlisle Cynthia | Officer | A-Award | A | Common Stock, $1 par value | 17,806 | 0.00 | — | 17,806 | D | ↗ |
| 2026-02-23 | Carlisle Cynthia | Officer | — | — | Common Stock, $1 par value | 0 | 0.00 | — | 0 | D | ↗ |
| 2026-02-13 | McDonnell Michael R. | Director | A-Award | A | Common Stock, $1 par value | 1,811 | 0.00 | — | 1,811 | D | ↗ |
| 2026-02-09 | Soriano Maria Cecilia | Officer | A-Award | A | Common Stock, $1 par value | 2,273 | 0.00 | — | 56,924 | D | ↗ |
| 2026-02-09 | Rosenbloom David S. | Officer | F-InKind | D | Common Stock, $1 par value | 5,225 | 21.73 | 113.5K | 119,464 | D | ↗ |
| 2026-02-09 | Rasul Reazur | Officer | A-Award | A | Common Stock, $1 par value | 18,951 | 0.00 | — | 145,616 | D | ↗ |
| 2026-02-09 | Grade Joel T. | Officer | F-InKind | D | Common Stock, $1 par value | 9,144 | 21.73 | 198.7K | 236,904 | D | ↗ |
| 2025-12-12 | Mason Jeanne K | Officer | F-InKind | D | Common Stock, $1 par value | 650 | 19.15 | 12.4K | 199,853 | D | ↗ |
| 2025-12-01 | Soriano Maria Cecilia | Officer | — | — | Common Stock, $1 par value | 0 | 0.00 | — | 54,623 | D | ↗ |
| 2025-12-01 | Grade Joel T. | Officer | F-InKind | D | Common Stock, $1 par value | 8,288 | 19.08 | 158.1K | 215,151 | D | ↗ |
| 2025-09-02 | Sonig Alok | Officer | F-InKind | D | Common Stock, $1 par value | 3,191 | 24.17 | 77.1K | 128,219 | D | ↗ |
| 2025-09-02 | Hider Andrew P. | Director / Officer | A-Award | A | Common Stock, $1 par value | 236,237 | 0.00 | — | 236,237 | D | ↗ |
| 2025-09-02 | Grade Joel T. | Officer | A-Award | A | Common Stock, $1 par value | 102,712 | 0.00 | — | 222,560 | D | ↗ |
| 2025-09-02 | Borzi James W | Officer | F-InKind | D | Common Stock, $1 par value | 1,848 | 24.17 | 44.7K | 71,948 | D | ↗ |
| 2025-08-19 | Shafer David Brent | Director | F-InKind | D | Common Stock, $1 par value | 31,337 | 24.33 | 762.4K | 59,446 | D | ↗ |
| 2025-08-19 | Hider Andrew P. | Director / Officer | — | — | Common Stock, $1 par value | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-06-02 | Rosenbloom David S. | Officer | F-InKind | D | Common Stock, $1 par value | 16,548 | 29.55 | 489.0K | 106,327 | D | ↗ |
| 2025-05-06 | Wilkes David S. | Director | A-Award | A | Common Stock, $1 par value | 7,183 | 0.00 | — | 23,906 | D | ↗ |
| 2025-05-06 | Wendell Amy McBride | Director | A-Award | A | Common Stock, $1 par value | 7,183 | 0.00 | — | 31,222 | D | ↗ |
| 2025-05-06 | Smith Cathy R | Director | A-Award | A | Common Stock, $1 par value | 7,183 | 0.00 | — | 30,345 | D | ↗ |
| 2025-05-06 | SCHLICHTING NANCY M | Director | A-Award | A | Common Stock, $1 par value | 7,183 | 0.00 | — | 21,850 | D | ↗ |
| 2025-05-06 | RUSCKOWSKI STEPHEN H | Director | A-Award | A | Common Stock, $1 par value | 7,183 | 0.00 | — | 16,499 | D | ↗ |
| 2025-05-06 | Oesterle Stephen N. | Director | A-Award | A | Common Stock, $1 par value | 7,183 | 0.00 | — | 35,847 | D | ↗ |
| 2025-05-06 | MORRISON PATRICIA | Director | A-Award | A | Common Stock, $1 par value | 7,183 | 0.00 | — | 29,137 | D | ↗ |
| 2025-05-06 | Craig Jeffrey A | Director | A-Award | A | Common Stock, $1 par value | 7,183 | 0.00 | — | 10,672 | D | ↗ |
| 2025-05-06 | Ampofo William A. II | Director | A-Award | A | Common Stock, $1 par value | 7,183 | 0.00 | — | 17,299 | D | ↗ |
| 2025-03-06 | Zielinski Anita A | Officer | A-Award | A | Common Stock, $1 par value | 17,123 | 0.00 | — | 17,123 | D | ↗ |
| 2025-03-06 | Sonig Alok | Officer | A-Award | A | Common Stock, $1 par value | 29,966 | 0.00 | — | 130,298 | D | ↗ |
| 2025-03-06 | Rosenbloom David S. | Officer | A-Award | A | Common Stock, $1 par value | 17,658 | 0.00 | — | 122,438 | D | ↗ |
| 2025-03-06 | Rasul Reazur | Officer | A-Award | A | Common Stock, $1 par value | 26,220 | 0.00 | — | 124,614 | D | ↗ |
| 2025-03-06 | Mason Jeanne K | Officer | F-InKind | D | Common Stock, $1 par value | 4,375 | 35.44 | 155.1K | 183,963 | D | ↗ |
| 2025-03-06 | Knight Heather | Officer | A-Award | A | Stock Option (Right to Buy) | 118,934 | 35.44 | 4.22M | 118,934 | D | ↗ |
| 2025-03-06 | Grade Joel T. | Officer | F-InKind | D | Common Stock, $1 par value | 4,306 | 35.44 | 152.6K | 88,896 | D | ↗ |
| 2025-03-06 | Borzi James W | Officer | A-Award | A | Stock Option (Right to Buy) | 33,302 | 35.44 | 1.18M | 33,302 | D | ↗ |
| 2025-03-03 | Sonig Alok | Officer | F-InKind | D | Common Stock, $1 par value | 1,936 | 34.86 | 67.5K | 111,171 | D | ↗ |
| 2025-03-03 | Rosenbloom David S. | Officer | F-InKind | D | Common Stock, $1 par value | 1,312 | 34.86 | 45.7K | 109,703 | D | ↗ |
| 2025-03-03 | Rasul Reazur | Officer | F-InKind | D | Common Stock, $1 par value | 1,987 | 34.86 | 69.3K | 107,735 | D | ↗ |
| 2025-03-03 | Mason Jeanne K | Officer | F-InKind | D | Common Stock, $1 par value | 1,479 | 34.86 | 51.6K | 188,339 | D | ↗ |
| 2025-03-03 | Knight Heather | Officer | F-InKind | D | Common Stock, $1 par value | 3,344 | 34.86 | 116.6K | 155,323 | D | ↗ |
| 2025-03-03 | Borzi James W | Officer | F-InKind | D | Common Stock, $1 par value | 1,339 | 34.86 | 46.7K | 66,407 | D | ↗ |
| 2025-02-21 | Zielinski Anita A | Officer | — | — | Common Stock, $1 par value | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-02-05 | Shafer David Brent | Director / Officer | A-Award | A | Common Stock, $1 par value | 76,289 | 0.00 | — | 89,841 | D | ↗ |
| 2025-02-03 | Shafer David Brent | Director / Officer | — | — | Common Stock, $1 par value | 0 | 0.00 | — | 13,552 | D | ↗ |
| 2025-01-31 | Toth Christopher A. | Officer | F-InKind | D | Common Stock, $1 par value | 25,372 | 32.56 | 826.1K | 105,186 | D | ↗ |
| 2024-12-31 | Toth Christopher A. | Officer | F-InKind | D | Common Stock, $1 par value | 32,610 | 29.16 | 950.9K | 183,876 | D | ↗ |
| 2024-12-13 | ALMEIDA JOSE E | Officer | F-InKind | D | Common Stock, $1 par value | 5,966 | 30.32 | 180.9K | 243,589 | D | ↗ |
| 2024-12-02 | Rasul Reazur | Officer | F-InKind | D | Common Stock, $1 par value | 2,032 | 33.55 | 68.2K | 109,116 | D | ↗ |
| 2024-12-02 | Knight Heather | Officer | F-InKind | D | Common Stock, $1 par value | 6,041 | 33.55 | 202.7K | 157,674 | D | ↗ |
| 2024-12-02 | Grade Joel T. | Officer | F-InKind | D | Common Stock, $1 par value | 6,612 | 33.55 | 221.8K | 92,457 | D | ↗ |
| 2024-09-09 | Craig Jeffrey A | Director | A-Award | A | Common Stock, $1 par value | 3,472 | 0.00 | — | 3,472 | — | ↗ |
| 2024-09-08 | Craig Jeffrey A | Director | — | D | Common Stock, $1 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-03 | Sonig Alok | Officer | F-InKind | D | Common Stock, $1 par value | 3,054 | 37.85 | 115.6K | 111,603 | — | ↗ |
| 2024-09-03 | Borzi James W | Officer | F-InKind | D | Common Stock, $1 par value | 1,685 | 37.85 | 63.8K | 66,853 | — | ↗ |
| 2024-06-03 | Toth Christopher A. | Officer | F-InKind | D | Common Stock, $1 par value | 15,202 | 34.08 | 518.1K | 213,282 | — | ↗ |
| 2024-06-03 | Rosenbloom David S. | Officer | F-InKind | D | Common Stock, $1 par value | 784 | 34.08 | 26.7K | 108,580 | — | ↗ |
| 2024-05-07 | Wilkes David S. | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 16,274 | — | ↗ |
| 2024-05-07 | Wendell Amy McBride | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 23,876 | — | ↗ |
| 2024-05-07 | WILVER PETER M | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 13,267 | — | ↗ |
| 2024-05-07 | Smith Cathy R | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 22,545 | — | ↗ |
| 2024-05-07 | Shafer David Brent | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 13,257 | — | ↗ |
| 2024-05-07 | SCHLICHTING NANCY M | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 14,278 | — | ↗ |
| 2024-05-07 | RUSCKOWSKI STEPHEN H | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 9,068 | — | ↗ |
| 2024-05-07 | Oesterle Stephen N. | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 27,901 | — | ↗ |
| 2024-05-07 | MORRISON PATRICIA | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 21,367 | — | ↗ |
| 2024-05-07 | Ampofo William A. II | Director | A-Award | A | Common Stock, $1 par value | 5,952 | 0.00 | — | 9,847 | — | ↗ |
| 2024-03-06 | Toth Christopher A. | Officer | A-Award | A | Common Stock, $1 par value | 119,076 | 0.00 | — | 227,761 | — | ↗ |
| 2024-03-06 | Stevens Brian | Officer | A-Award | A | Common Stock, $1 par value | 14,289 | 0.00 | — | 67,538 | — | ↗ |
| 2024-03-06 | Sonig Alok | Officer | A-Award | A | Common Stock, $1 par value | 83,353 | 0.00 | — | 113,454 | — | ↗ |
| 2024-03-06 | Rosenbloom David S. | Officer | A-Award | A | Common Stock, $1 par value | 53,584 | 0.00 | — | 108,989 | — | ↗ |
| 2024-03-06 | Rasul Reazur | Officer | A-Award | A | Common Stock, $1 par value | 83,353 | 0.00 | — | 109,187 | — | ↗ |
| 2024-03-06 | Mason Jeanne K | Officer | A-Award | A | Common Stock, $1 par value | 47,630 | 0.00 | — | 188,481 | — | ↗ |
| 2024-03-06 | Knight Heather | Officer | A-Award | A | Common Stock, $1 par value | 107,168 | 0.00 | — | 160,330 | — | ↗ |
| 2024-03-06 | Grade Joel T. | Officer | A-Award | A | Common Stock, $1 par value | 42,867 | 0.00 | — | 96,623 | — | ↗ |
| 2024-03-06 | Borzi James W | Officer | A-Award | A | Common Stock, $1 par value | 33,341 | 0.00 | — | 67,735 | — | ↗ |
| 2024-03-06 | ALMEIDA JOSE E | Officer | A-Award | A | Common Stock, $1 par value | 142,891 | 0.00 | — | 244,924 | — | ↗ |
| 2024-03-04 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 545 | 42.50 | 23.2K | 53,249 | — | ↗ |
| 2024-03-04 | Rasul Reazur | Officer | F-InKind | D | Common Stock, $1 par value | 522 | 42.50 | 22.2K | 25,834 | — | ↗ |
| 2024-03-04 | Mason Jeanne K | Officer | F-InKind | D | Common Stock, $1 par value | 475 | 42.50 | 20.2K | 140,851 | — | ↗ |
| 2024-03-04 | Knight Heather | Officer | F-InKind | D | Common Stock, $1 par value | 1,320 | 42.50 | 56.1K | 53,162 | — | ↗ |
| 2024-03-04 | Borzi James W | Officer | F-InKind | D | Common Stock, $1 par value | 420 | 42.50 | 17.9K | 34,394 | — | ↗ |
| 2024-03-04 | ALMEIDA JOSE E | Officer | F-InKind | D | Common Stock, $1 par value | 4,779 | 42.50 | 203.1K | 102,033 | — | ↗ |
| 2024-03-01 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 673 | 41.01 | 27.6K | 53,795 | — | ↗ |
| 2024-03-01 | Sonig Alok | Officer | F-InKind | D | Common Stock, $1 par value | 1,832 | 41.01 | 75.1K | 30,101 | — | ↗ |
| 2024-03-01 | Rosenbloom David S. | Officer | F-InKind | D | Common Stock, $1 par value | 1,416 | 41.01 | 58.1K | 55,405 | — | ↗ |
| 2024-03-01 | Rasul Reazur | Officer | F-InKind | D | Common Stock, $1 par value | 1,538 | 41.01 | 63.1K | 26,357 | — | ↗ |
| 2024-03-01 | Mason Jeanne K | Officer | S-Sale | D | Common Stock, $1 par value | 64,488 | 40.61 | 2.62M | 142,290 | — | ↗ |
| 2024-03-01 | Knight Heather | Officer | F-InKind | D | Common Stock, $1 par value | 2,154 | 41.01 | 88.3K | 54,483 | — | ↗ |
| 2024-03-01 | Borzi James W | Officer | F-InKind | D | Common Stock, $1 par value | 852 | 41.01 | 34.9K | 34,814 | — | ↗ |
| 2024-03-01 | ALMEIDA JOSE E | Officer | F-InKind | D | Common Stock, $1 par value | 9,701 | 41.01 | 397.8K | 106,812 | — | ↗ |
| 2024-02-12 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 284 | 40.31 | 11.4K | 54,469 | — | ↗ |
| 2024-02-12 | Rasul Reaz | Officer | A-Award | A | Common Stock, $1 par value | 716 | 0.00 | — | 28,143 | — | ↗ |
| 2024-02-12 | Mason Jeanne K | Officer | F-InKind | D | Common Stock, $1 par value | 1,463 | 40.31 | 59.0K | 142,290 | — | ↗ |
| 2024-02-12 | Knight Heather | Officer | F-InKind | D | Common Stock, $1 par value | 356 | 40.31 | 14.4K | 56,602 | — | ↗ |
| 2024-02-12 | Borzi James W | Officer | F-InKind | D | Common Stock, $1 par value | 1,311 | 40.31 | 52.8K | 35,666 | — | ↗ |
| 2024-02-12 | ALMEIDA JOSE E | Officer | F-InKind | D | Common Stock, $1 par value | 10,863 | 40.31 | 437.9K | 116,513 | — | ↗ |
| 2023-12-01 | Stevens Brian | Officer | A-Award | A | Common Stock, $1 par value | 13,994 | 0.00 | — | 53,532 | — | ↗ |
| 2023-12-01 | Grade Joel T. | Officer | A-Award | A | Stock Option (Right to Buy) | 102,273 | 36.55 | 3.74M | 102,273 | — | ↗ |
| 2023-10-18 | Grade Joel T. | Officer | — | D | Common Stock, $1 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-01 | Sonig Alok | Officer | F-InKind | D | Common Stock, $1 par value | 2,059 | 40.60 | 83.6K | 31,512 | — | ↗ |
| 2023-09-01 | Borzi James W | Officer | A-Award | A | Common Stock, $1 par value | 12,016 | 0.00 | — | 32,300 | — | ↗ |
| 2023-08-21 | RUSCKOWSKI STEPHEN H | Director | A-Award | A | Common Stock, $1 par value | 3,049 | 0.00 | — | 3,049 | — | ↗ |
| 2023-06-29 | Ampofo William A. II | Director | A-Award | A | Common Stock, $ par value | 3,811 | 0.00 | — | 3,811 | — | ↗ |
| 2023-06-01 | Toth Christopher A. | Officer | A-Award | A | Common Stock, $1 par value | 106,358 | 0.00 | — | 106,358 | — | ↗ |
| 2023-06-01 | Stevens Brian | Officer | A-Award | A | Common Stock, $1 par value | 5,909 | 0.00 | — | 38,982 | — | ↗ |
| 2023-06-01 | Rosenbloom David S. | Officer | F-InKind | D | Common Stock, $1 par value | 762 | 41.23 | 31.4K | 55,645 | — | ↗ |
| 2023-05-02 | Wilkes David S. | Director | A-Award | A | Common Stock, $1 par value | 4,573 | 0.00 | — | 10,034 | — | ↗ |
| 2023-05-02 | Wendell Amy McBride | Director | A-Award | A | Common Stock, $1 par value | 4,573 | 0.00 | — | 17,894 | — | ↗ |
| 2023-05-02 | WILVER PETER M | Director | A-Award | A | Common Stock, $1 par value | 4,573 | 0.00 | — | 7,111 | — | ↗ |
| 2023-05-02 | Smith Cathy R | Director | A-Award | A | Common Stock, $1 par value | 4,573 | 0.00 | — | 16,130 | — | ↗ |
| 2023-05-02 | Shafer David Brent | Director | A-Award | A | Common Stock, $1 par value | 4,573 | 0.00 | — | 7,101 | — | ↗ |
| 2023-05-02 | SCHLICHTING NANCY M | Director | A-Award | A | Common Stock, $1 par value | 4,573 | 0.00 | — | 8,099 | — | ↗ |
| 2023-05-02 | Oesterle Stephen N. | Director | A-Award | A | Common Stock, $1 par value | 4,573 | 0.00 | — | 21,336 | — | ↗ |
| 2023-05-02 | Mahoney Michael F | Director | A-Award | A | Common Stock, $1 par value | 4,573 | 0.00 | — | 9,692 | — | ↗ |
| 2023-05-02 | MORRISON PATRICIA | Director | A-Award | A | Common Stock, $1 par value | 4,573 | 0.00 | — | 14,984 | — | ↗ |
| 2023-03-20 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 161 | 38.19 | 6.1K | 32,896 | — | ↗ |
| 2023-03-20 | STROUCKEN ALBERT P L | Director | S-Sale | D | Common Stock, $1 par value | 3,930 | 37.52 | 147.5K | 36,835 | — | ↗ |
| 2023-03-03 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 184 | 39.94 | 7.3K | 33,058 | — | ↗ |
| 2023-03-03 | Rasul Reaz | Officer | F-InKind | D | Common Stock, $1 par value | 148 | 39.94 | 5.9K | 26,917 | — | ↗ |
| 2023-03-03 | Knight Heather | Officer | F-InKind | D | Common Stock, $1 par value | 220 | 39.94 | 8.8K | 53,322 | — | ↗ |
| 2023-03-02 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 418 | 39.62 | 16.6K | 33,242 | — | ↗ |
| 2023-03-02 | SACCARO JAMES | Officer | F-InKind | D | Common Stock, $1 par value | 1,061 | 39.62 | 42.0K | 177,899 | — | ↗ |
| 2023-03-02 | Rasul Reaz | Officer | F-InKind | D | Common Stock, $1 par value | 416 | 39.62 | 16.5K | 27,066 | — | ↗ |
| 2023-03-02 | Mason Jeanne K | Officer | F-InKind | D | Common Stock, $1 par value | 460 | 39.62 | 18.2K | 138,821 | — | ↗ |
| 2023-03-02 | Kunzler Jacqueline | Officer | F-InKind | D | Common Stock, $1 par value | 271 | 39.62 | 10.7K | 22,625 | — | ↗ |
| 2023-03-02 | Knight Heather | Officer | F-InKind | D | Common Stock, $1 par value | 1,067 | 39.62 | 42.3K | 53,543 | — | ↗ |
| 2023-03-02 | Franzi Cristiano | Officer | F-InKind | D | Common Stock, $1 par value | 146 | 39.62 | 5.8K | 102,145 | — | ↗ |
| 2023-03-02 | Borzi James W | Officer | F-InKind | D | Common Stock, $1 par value | 474 | 39.62 | 18.8K | 20,078 | — | ↗ |
| 2023-03-02 | ALMEIDA JOSE E | Officer | F-InKind | D | Common Stock, $1 par value | 4,642 | 39.62 | 183.9K | 408,453 | — | ↗ |
| 2023-03-01 | Stevens Brian | Officer | A-Award | A | Stock Option (Right to Buy) | 14,072 | 39.06 | 549.7K | 14,072 | — | ↗ |
| 2023-03-01 | Sonig Alok | Officer | — | D | Common Stock, $1 par value | 0 | 0.00 | — | 17,798 | — | ↗ |
| 2023-03-01 | SACCARO JAMES | Officer | A-Award | A | Common Stock, $1 par value | 22,217 | 0.00 | — | 178,961 | — | ↗ |
| 2023-03-01 | Rosenbloom David S. | Officer | A-Award | A | Stock Option (Right to Buy) | 57,568 | 39.06 | 2.25M | 57,568 | — | ↗ |
| 2023-03-01 | Rasul Reaz | Officer | — | D | Stock Option (Right to Buy) | 6,417 | 50.77 | 325.8K | 0 | — | ↗ |
| 2023-03-01 | Mason Jeanne K | Officer | A-Award | A | Common Stock, $1 par value | 10,491 | 0.00 | — | 139,282 | — | ↗ |
| 2023-03-01 | Kunzler Jacqueline | Officer | A-Award | A | Stock Option (Right to Buy) | 25,586 | 39.06 | 999.4K | 25,586 | — | ↗ |
| 2023-03-01 | Knight Heather | Officer | — | D | Stock Option (Right to Buy) | 18,861 | 74.73 | 1.41M | 0 | — | ↗ |
| 2023-03-01 | Franzi Cristiano | Officer | A-Award | A | Stock Option (Right to Buy) | 63,965 | 39.06 | 2.50M | 63,965 | — | ↗ |
| 2023-03-01 | Flynn Steven | Officer | A-Award | A | Stock Option (Right to Buy) | 25,586 | 39.06 | 999.4K | 25,586 | — | ↗ |
| 2023-03-01 | Borzi James W | Officer | A-Award | A | Stock Option (Right to Buy) | 35,820 | 39.06 | 1.40M | 35,820 | — | ↗ |
| 2023-03-01 | ALMEIDA JOSE E | Officer | A-Award | A | Common Stock, $1 par value | 67,884 | 0.00 | — | 413,096 | — | ↗ |
| 2023-02-21 | Kunzler Jacqueline | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,163 | 37.82 | 157.4K | 0 | — | ↗ |
| 2023-02-13 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 224 | 40.50 | 9.1K | 26,872 | — | ↗ |
| 2023-02-13 | SACCARO JAMES | Officer | F-InKind | D | Common Stock, $1 par value | 1,059 | 40.50 | 42.9K | 156,744 | — | ↗ |
| 2023-02-13 | Mason Jeanne K | Officer | F-InKind | D | Common Stock, $1 par value | 1,061 | 40.50 | 43.0K | 128,791 | — | ↗ |
| 2023-02-13 | Kunzler Jacqueline | Officer | A-Award | A | Common Stock, $1 par value | 2,068 | 0.00 | — | 17,090 | — | ↗ |
| 2023-02-13 | Franzi Cristiano | Officer | F-InKind | D | Common Stock, $1 par value | 275 | 40.50 | 11.1K | 62,179 | — | ↗ |
| 2023-02-13 | Flynn Steven | Officer | A-Award | A | Common Stock, $1 par value | 516 | 0.00 | — | 12,502 | — | ↗ |
| 2023-02-13 | ALMEIDA JOSE E | Officer | F-InKind | D | Common Stock, $1 par value | 10,053 | 40.50 | 407.1K | 345,212 | — | ↗ |
| 2023-01-17 | Mason Jeanne K | Officer | M-Exempt | A | Common Stock, $1 par value | 59,477 | 37.82 | 2.25M | 185,708 | — | ↗ |
| 2022-09-01 | Borzi James W | Officer | F-InKind | D | Common Stock, $1 par value | 4,649 | 56.76 | 263.9K | 11,822 | — | ↗ |
| 2022-07-12 | Flynn Steven | Officer | — | D | Stock Option (Right to Buy) | 15,207 | 77.15 | 1.17M | 0 | — | ↗ |
| 2022-06-01 | Rosenbloom David S. | Officer | A-Award | A | Stock Option (Right to Buy) | 33,442 | 0.00 | — | 33,442 | — | ↗ |
| 2022-05-10 | WILVER PETER M | Director | A-Award | A | Common Stock, $1 par value | 2,481 | 0.00 | — | 2,481 | — | ↗ |
| 2022-05-10 | Shafer David Brent | Director | A-Award | A | Common Stock, $1 par value | 2,481 | 0.00 | — | 2,481 | — | ↗ |
| 2022-05-03 | Wilkes David S. | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 5,339 | — | ↗ |
| 2022-05-03 | Wendell Amy McBride | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 13,168 | — | ↗ |
| 2022-05-03 | Smith Cathy R | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 11,299 | — | ↗ |
| 2022-05-03 | STROUCKEN ALBERT P L | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 36,834 | — | ↗ |
| 2022-05-03 | SCHLICHTING NANCY M | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 3,451 | — | ↗ |
| 2022-05-03 | Oesterle Stephen N. | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 16,389 | — | ↗ |
| 2022-05-03 | Mahoney Michael F | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 5,004 | — | ↗ |
| 2022-05-03 | MORRISON PATRICIA | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 10,178 | — | ↗ |
| 2022-05-03 | HELLMAN PETER S | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 30,335 | — | ↗ |
| 2022-05-03 | Chen Thomas F | Director | A-Award | A | Common Stock, $1 par value | 2,706 | 0.00 | — | 15,740 | — | ↗ |
| 2022-04-18 | Rosenbloom David S. | Officer | — | D | Common Stock, $1 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-05 | STROUCKEN ALBERT P L | Director | M-Exempt | D | Stock Option (Right to Buy) | 4,020 | 29.52 | 118.7K | 0 | — | ↗ |
| 2022-04-05 | HELLMAN PETER S | Director | S-Sale | D | Common Stock, $1 par value | 1,193 | 76.63 | 91.4K | 27,629 | — | ↗ |
| 2022-04-01 | FORSYTH JOHN D | Director | S-Sale | D | Common Stock, $1 par value | 1,005 | 77.68 | 78.1K | 27,029 | — | ↗ |
| 2022-03-21 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 157 | 79.05 | 12.4K | 25,993 | — | ↗ |
| 2022-03-03 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 172 | 85.19 | 14.7K | 26,151 | — | ↗ |
| 2022-03-02 | Stevens Brian | Officer | A-Award | A | Stock Option (Right to Buy) | 8,269 | 85.23 | 704.8K | 8,269 | — | ↗ |
| 2022-03-02 | SACCARO JAMES | Officer | A-Award | A | Stock Option (Right to Buy) | 49,613 | 0.00 | — | 49,613 | — | ↗ |
| 2022-03-02 | Mason Jeanne K | Officer | A-Award | A | Common Stock, $1 par value | 5,054 | 0.00 | — | 126,153 | — | ↗ |
| 2022-03-02 | Martin Sean | Officer | A-Award | A | Common Stock, $1 par value | 6,688 | 0.00 | — | 52,632 | — | ↗ |
| 2022-03-02 | Kunzler Jacqueline | Officer | A-Award | A | Stock Option (Right to Buy) | 13,781 | 0.00 | — | 13,781 | — | ↗ |
| 2022-03-02 | Frye Andrew | Officer | A-Award | A | Stock Option (Right to Buy) | 34,454 | 0.00 | — | 34,454 | — | ↗ |
| 2022-03-02 | Franzi Cristiano | Officer | A-Award | A | Stock Option (Right to Buy) | 37,899 | 0.00 | — | 37,899 | — | ↗ |
| 2022-03-02 | Borzi James W | Officer | A-Award | A | Common Stock, $1 par value | 4,162 | 0.00 | — | 16,356 | — | ↗ |
| 2022-03-02 | Accogli Giuseppe | Officer | A-Award | A | Common Stock, $1 par value | 11,891 | 0.00 | — | 76,495 | — | ↗ |
| 2022-03-02 | ALMEIDA JOSE E | Officer | A-Award | A | Common Stock, $1 par value | 32,699 | 0.00 | — | 318,435 | — | ↗ |
| 2022-03-01 | FORSYTH JOHN D | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,005 | 29.52 | 29.7K | 2,010 | — | ↗ |
| 2022-02-28 | Stevens Brian | Officer | F-InKind | D | Common Stock, $1 par value | 172 | 84.97 | 14.6K | 13,839 | — | ↗ |
| 2022-02-14 | Mason Jeanne K | Officer | M-Exempt | A | Common Stock, $1 par value | 54,143 | 30.95 | 1.68M | 175,242 | — | ↗ |
| 2022-02-10 | Stevens Brian | Officer | A-Award | A | Common Stock, $1 par value | 249 | 0.00 | — | 16,255 | — | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Joel Grade Former Executive Vice President and CFO | 827.8K | — | 5.81M | 1.05M | 459.0K | 63.7K | 8.21M | 83.55% | ↗ |
| 2 | 2025 | José E. Almeida Former Chair of the Board, President and CEO | 660.4K | — | — | — | — | 7.01M | 7.67M | 0.00% | ↗ |
| 3 | 2025 | Reazur Rasul Executive Vice President and Group President, Healthcare Systems & Technologies | 800.0K | — | 2.95M | 931.5K | 488.0K | 73.3K | 5.25M | 74.05% | ↗ |
| 4 | 2025 | Alok Sonig Former Executive Vice President and Group President, Pharmaceuticals | 779.7K | — | 3.38M | 1.06M | — | 19.6K | 5.24M | 84.74% | ↗ |
| 5 | 2024 | José E. Almeida Former Chair of the Board, President and Chief Executive Officer | 1.30M | — | 14.32M | — | 2.02M | 435.6K | 18.07M | 79.24% | ↗ |
| 6 | 2024 | José E. Almeida Former Chair of the Board, President and CEO | 1.30M | — | 14.32M | — | 2.02M | 435.6K | 18.07M | 79.24% | ↗ |
| 7 | 2024 | Christopher Toth Former Executive Vice President and Group President, Kidney Care | 1.00M | — | 5.12M | — | 1.39M | 78.2K | 7.58M | 67.49% | ↗ |
| 8 | 2024 | Heather Knight Executive Vice President, Chief Operating Officer and Interim Group President, Medical Products & Therapies | 883.3K | — | 4.61M | — | 1.04M | 66.5K | 6.60M | 69.84% | ↗ |
| 9 | 2024 | Joel Grade Executive Vice President and Chief Financial Officer | 810.0K | 500.0K | 4.30M | — | 839.6K | 62.2K | 6.51M | 66.01% | ↗ |
| 10 | 2024 | Joel Grade Former Executive Vice President and CFO | 810.0K | 500.0K | 4.30M | — | 839.6K | 62.2K | 6.51M | 66.01% | ↗ |
| 11 | 2024 | Alok Sonig Former Executive Vice President and Group President, Pharmaceuticals | 787.5K | — | 3.58M | — | 904.0K | 71.0K | 5.35M | 67.03% | ↗ |
| 12 | 2024 | Alok Sonig Executive Vice President and Group President, Pharmaceuticals | 787.5K | — | 3.58M | — | 904.0K | 71.0K | 5.35M | 67.03% | ↗ |
| 13 | 2023 | José E. Almeida Chair of the Board, President and Chief Executive Officer | 1.30M | — | 7.53M | 2.64M | 2.19M | 136.1K | 13.79M | 73.71% | ↗ |
| 14 | 2023 | José E. Almeida Former Chair of the Board, President and Chief Executive Officer | 1.30M | — | 7.53M | 2.64M | 2.19M | 136.1K | 13.79M | 73.71% | ↗ |
| 15 | 2023 | Christopher Toth Former Executive Vice President and Group President, Kidney Care | 586.3K | 3.20M | 4.39M | — | 730.2K | 738.6K | 9.64M | 45.49% | ↗ |
| 16 | 2023 | Christopher Toth Executive Vice President and Group President, Kidney Care | 586.3K | 3.20M | 4.39M | — | 730.2K | 738.6K | 9.64M | 45.49% | ↗ |
| 17 | 2023 | Cristiano Franzi Former Senior Vice President and President, EMEA | 525.4K | — | 2.67M | 598.9K | 455.5K | 2.63M | 6.88M | 47.55% | ↗ |
| 18 | 2023 | Joel Grade Executive Vice President and Chief Financial Officer | 164.4K | — | 3.64M | 902.9K | 167.7K | 4.6K | 4.88M | 93.10% | ↗ |
| 19 | 2023 | Heather Knight Executive Vice President and Group President, Medical Products & Therapies | 791.5K | — | 2.40M | 838.5K | 771.1K | 64.1K | 4.86M | 66.53% | ↗ |
| 20 | 2023 | Heather Knight Executive Vice President, Chief Operating Officer and Interim Group President, Medical Products & Therapies | 791.5K | — | 2.40M | 838.5K | 771.1K | 64.1K | 4.86M | 66.53% | ↗ |
| 21 | 2023 | Alok Sonig Executive Vice President and Group President, Pharmaceuticals | 725.0K | — | 1.71M | 598.9K | 794.6K | 36.8K | 3.87M | 59.74% | ↗ |
| 22 | 2023 | James K. Saccaro Former Executive Vice President and Chief Financial Officer | 354.6K | — | 2.46M | 862.4K | — | 25.2K | 3.71M | 89.75% | ↗ |
| 23 | 2023 | Brian C. Stevens Senior Vice President, Chief Accounting Officer & Controller and Former Interim Chief Financial Officer | 517.5K | 350.0K | 1.14M | 131.8K | 344.1K | 43.8K | 2.53M | 50.37% | ↗ |
| 24 | 2022 | José E. Almeida Chair of the Board, President and Chief Executive Officer | 1.30M | — | 8.73M | 2.76M | 675.7K | 121.8K | 13.59M | 84.56% | ↗ |
| 25 | 2022 | José E. Almeida Former Chair of the Board, President and Chief Executive Officer | 1.30M | — | 8.73M | 2.76M | 675.7K | 121.8K | 13.59M | 84.56% | ↗ |
| 26 | 2022 | José E. Almeida Chair, President and Chief Executive Officer | 1.30M | — | 8.73M | 2.76M | 675.7K | 121.8K | 13.59M | 84.56% | ↗ |
| 27 | 2022 | James K. Saccaro Former Executive Vice President and Chief Financial Officer | 834.6K | — | 6.10M | 903.4K | 267.8K | 102.3K | 8.21M | 85.32% | ↗ |
| 28 | 2022 | James K. Saccaro Executive Vice President and Chief Financial Officer | 834.6K | — | 6.10M | 903.4K | 267.8K | 102.3K | 8.21M | 85.32% | ↗ |
| 29 | 2022 | Giuseppe Accogli Executive Vice President and Chief Operating Officer | 875.0K | — | 5.88M | 1.00M | — | 106.2K | 7.86M | 87.52% | ↗ |
| 30 | 2022 | David Rosenbloom Senior Vice President and General Counsel | 512.5K | — | 4.31M | 577.4K | 137.2K | 24.3K | 5.56M | 87.88% | ↗ |
| 31 | 2022 | Cristiano Franzi Former Senior Vice President and President, EMEA | 824.4K | — | 3.26M | 690.1K | 310.5K | 169.2K | 5.26M | 75.20% | ↗ |
| 32 | 2022 | Cristiano Franzi Senior Vice President and President, EMEA | 824.4K | — | 3.26M | 690.1K | 310.5K | 169.2K | 5.26M | 75.20% | ↗ |
| 33 | 2021 | José E. Almeida Chair of the Board, President and Chief Executive Officer | 1.30M | — | 6.48M | 5.44M | 2.36M | 50.3K | 15.63M | 76.24% | ↗ |
| 34 | 2021 | José E. Almeida Chair, President and Chief Executive Officer | 1.30M | — | 6.48M | 5.44M | 2.36M | 50.3K | 15.63M | 76.24% | ↗ |
| 35 | 2021 | José E. Almeida Chairman of the Board, President and Chief Executive Officer | 1.30M | — | 6.48M | 5.44M | 2.36M | 50.3K | 15.63M | 76.24% | ↗ |
| 36 | 2021 | Giuseppe Accogli Executive Vice President and Chief Operating Officer | 824.4K | — | 2.15M | 1.91M | 893.0K | 64.8K | 5.84M | 69.48% | ↗ |
| 37 | 2021 | Andrew Frye Senior Vice President, and President, APAC | 740.4K | — | 1.80M | 1.24M | 673.8K | 262.1K | 4.71M | 64.40% | ↗ |
| 38 | 2021 | James K. Saccaro Executive Vice President and Chief Financial Officer | 757.1K | — | 1.55M | 1.29M | 797.1K | 66.2K | 4.46M | 63.66% | ↗ |
| 39 | 2021 | James K. Saccaro Former Executive Vice President and Chief Financial Officer | 757.1K | — | 1.55M | 1.29M | 797.1K | 66.2K | 4.46M | 63.66% | ↗ |
| 40 | 2021 | Cristiano Franzi Former Senior Vice President and President, EMEA | 809.1K | — | 1.41M | 1.24M | 782.4K | 165.9K | 4.41M | 60.12% | ↗ |
| 41 | 2021 | Cristiano Franzi Senior Vice President and President, EMEA | 809.1K | — | 1.41M | 1.24M | 782.4K | 165.9K | 4.41M | 60.12% | ↗ |
| 42 | 2020 | José E. Almeida Chair, President and Chief Executive Officer | 1.30M | — | 8.37M | 6.12M | — | 70.9K | 15.87M | 91.36% | ↗ |
| 43 | 2020 | José E. Almeida Chairman of the Board, President and Chief Executive Officer | 1.30M | — | 8.37M | 6.12M | — | 70.9K | 15.87M | 91.36% | ↗ |
| 44 | 2020 | José E. Almeida Chairman of the Board, Chief Executive Officer and President | 1.30M | — | 8.37M | 6.12M | — | 70.9K | 15.87M | 91.36% | ↗ |
| 45 | 2020 | Giuseppe Accogli Senior Vice President and President, Americas & Global Business Units | 774.9K | — | 2.02M | 1.53M | 230.4K | 88.5K | 4.64M | 76.45% | ↗ |
| 46 | 2020 | Giuseppe Accogli Executive Vice President and Chief Operating Officer | 774.9K | — | 2.02M | 1.53M | 230.4K | 88.5K | 4.64M | 76.45% | ↗ |
| 47 | 2020 | Sean Martin Senior Vice President and General Counsel | 672.3K | — | 2.26M | 816.1K | 222.2K | 48.9K | 4.02M | 76.52% | ↗ |
| 48 | 2020 | Cristiano Franzi Senior Vice President, President, EMEA | 821.5K | — | 1.36M | 1.02M | 336.3K | 169.1K | 3.71M | 64.25% | ↗ |
| 49 | 2020 | Cristiano Franzi Senior Vice President and President, EMEA | 821.5K | — | 1.36M | 1.02M | 336.3K | 169.1K | 3.71M | 64.25% | ↗ |
| 50 | 2020 | James K. Saccaro Executive Vice President and Chief Financial Officer | 739.0K | — | 1.18M | 663.0K | 287.8K | 329.5K | 3.20M | 57.63% | ↗ |
| 51 | 2019 | José E. Almeida Chairman of the Board, President and Chief Executive Officer | 1.30M | — | 6.65M | 5.15M | 690.8K | 128.2K | 13.91M | 84.77% | ↗ |
| 52 | 2019 | José E. Almeida Chairman of the Board, Chief Executive Officer and President | 1.30M | — | 6.65M | 5.15M | 690.8K | 128.2K | 13.91M | 84.77% | ↗ |
| 53 | 2019 | James K. Saccaro Executive Vice President and Chief Financial Officer | 735.8K | — | 1.68M | 1.34M | — | 417.2K | 4.17M | 72.35% | ↗ |
| 54 | 2019 | Giuseppe Accogli Executive Vice President and Chief Operating Officer | 731.4K | — | 1.39M | 1.13M | 691.8K | 94.0K | 4.04M | 62.42% | ↗ |
| 55 | 2019 | Giuseppe Accogli Senior Vice President and President, Americas & Global Business Units | 731.4K | — | 1.39M | 1.13M | 691.8K | 94.0K | 4.04M | 62.42% | ↗ |
| 56 | 2019 | Giuseppe Accogli Senior Vice President and President, Americas | 731.4K | — | 1.39M | 1.13M | 691.8K | 94.0K | 4.04M | 62.42% | ↗ |
| 57 | 2019 | Sean Martin Senior Vice President and General Counsel | 648.7K | — | 1.06M | 823.5K | 593.9K | 83.3K | 3.21M | 58.73% | ↗ |
| 58 | 2019 | Cristiano Franzi Senior Vice President, President, EMEA | 727.6K | — | 844.5K | 823.5K | 611.2K | 160.9K | 3.17M | 52.66% | ↗ |
| 59 | 2019 | Cristiano Franzi Senior Vice President and President, EMEA | 727.6K | — | 844.5K | 823.5K | 611.2K | 160.9K | 3.17M | 52.66% | ↗ |
| 60 | 2018 | José E. Almeida Chairman of the Board, Chief Executive Officer and President | 1.30M | — | 6.73M | 4.90M | 2.58M | 134.5K | 15.65M | 74.32% | ↗ |
| 61 | 2018 | James K. Saccaro Executive Vice President and Chief Financial Officer | 714.5K | — | 1.67M | 1.27M | 883.7K | 115.5K | 4.65M | 63.19% | ↗ |
| 62 | 2018 | Brik V. Eyre Senior Vice President and President, Americas | 671.1K | — | 1.30M | 931.0K | 830.2K | 99.3K | 3.83M | 58.17% | ↗ |
| 63 | 2018 | Giuseppe Accogli Senior Vice President and President, Americas & Global Business Units | 706.6K | — | 1.07M | 980.0K | 827.5K | 186.5K | 3.77M | 54.40% | ↗ |
| 64 | 2018 | Giuseppe Accogli Senior Vice President and President, Americas | 706.6K | — | 1.07M | 980.0K | 827.5K | 186.5K | 3.77M | 54.40% | ↗ |
| 65 | 2018 | Giuseppe Accogli Senior Vice President and President, Global Businesses | 706.6K | — | 1.07M | 980.0K | 827.5K | 186.5K | 3.77M | 54.40% | ↗ |
| 66 | 2018 | Sean Martin Senior Vice President and General Counsel | 632.8K | — | 853.5K | 784.0K | 696.0K | 82.2K | 3.05M | 53.72% | ↗ |
| 67 | 2017 | José E. Almeida Chairman of the Board, Chief Executive Officer and President | 1.30M | — | 5.37M | 5.19M | 2.81M | 266.9K | 14.93M | 70.70% | ↗ |
| 68 | 2017 | James K. Saccaro Executive Vice President and Chief Financial Officer | 681.7K | — | 5.86M | 1.14M | 1.11M | 250.1K | 9.04M | 77.44% | ↗ |
| 69 | 2017 | Sean Martin Senior Vice President, General Counsel | 521.5K | 500.0K | 1.70M | 2.28M | 694.4K | 16.3K | 5.72M | 69.72% | ↗ |
| 70 | 2017 | Sean Martin Senior Vice President and General Counsel | 521.5K | 500.0K | 1.70M | 2.28M | 694.4K | 16.3K | 5.72M | 69.72% | ↗ |
| 71 | 2017 | Brik V. Eyre Senior Vice President, President, Americas | 654.1K | — | 2.62M | 1.04M | 902.9K | 116.6K | 5.33M | 68.63% | ↗ |
| 72 | 2017 | Brik V. Eyre Senior Vice President and President, Americas | 654.1K | — | 2.62M | 1.04M | 902.9K | 116.6K | 5.33M | 68.63% | ↗ |
| 73 | 2017 | Giuseppe Accogli Senior Vice President and President, Americas | 633.0K | — | 2.34M | 907.4K | 1.01M | 139.8K | 5.03M | 64.50% | ↗ |
| 74 | 2017 | Giuseppe Accogli Senior Vice President and President, Global Businesses | 633.0K | — | 2.34M | 907.4K | 1.01M | 139.8K | 5.03M | 64.50% | ↗ |
| 75 | 2017 | Giuseppe Accogli Senior Vice President, President, Global Businesses | 633.0K | — | 2.34M | 907.4K | 1.01M | 139.8K | 5.03M | 64.50% | ↗ |
| 76 | 2016 | José E. Almeida Chairman of the Board, Chief Executive Officer and President | 1.30M | — | 826.5K | — | 3.51M | 177.5K | 5.81M | 14.22% | ↗ |
| 77 | 2016 | Jill M. Schaaf Former Corporate Vice President, President, Renal | 204.1K | — | 530.1K | 630.8K | — | 3.20M | 4.56M | 25.46% | ↗ |
| 78 | 2016 | David P. Scharf Former Corporate Vice President, General Counsel | 678.8K | — | 931.4K | 919.9K | 952.0K | 560.3K | 4.04M | 45.80% | ↗ |
| 79 | 2016 | James K. Saccaro Executive Vice President and Chief Financial Officer | 644.4K | — | 941.5K | 1.18M | 1.06M | 196.8K | 4.02M | 52.81% | ↗ |
| 80 | 2016 | James K. Saccaro Corporate Vice President and Chief Financial Officer | 644.4K | — | 941.5K | 1.18M | 1.06M | 196.8K | 4.02M | 52.81% | ↗ |
| 81 | 2016 | Brik V. Eyre Senior Vice President, President, Americas | 618.5K | — | 832.0K | 985.6K | 955.0K | 87.9K | 3.48M | 52.24% | ↗ |
| 82 | 2016 | Brik V. Eyre Corporate Vice President, President, Hospital Products | 618.5K | — | 832.0K | 985.6K | 955.0K | 87.9K | 3.48M | 52.24% | ↗ |
| 83 | 2016 | Brik V. Eyre Senior Vice President and President, Americas | 618.5K | — | 832.0K | 985.6K | 955.0K | 87.9K | 3.48M | 52.24% | ↗ |
| 84 | 2016 | Giuseppe Accogli Senior Vice President, President, Global Businesses | 514.0K | 400.0K | 454.2K | 399.2K | 775.0K | 934.2K | 3.48M | 24.55% | ↗ |
| 85 | 2016 | Giuseppe Accogli Senior Vice President and President, Global Businesses | 514.0K | 400.0K | 454.2K | 399.2K | 775.0K | 934.2K | 3.48M | 24.55% | ↗ |
| 86 | 2016 | Giuseppe Accogli Corporate Vice President, President, Renal | 514.0K | 400.0K | 454.2K | 399.2K | 775.0K | 934.2K | 3.48M | 24.55% | ↗ |
| 87 | 2015 | Robert L. Parkinson, Jr., Former Chairman and Chief Executive Officer | 1.54M | — | 6.57M | 4.89M | 3.64M | 1.24M | 17.88M | 64.12% | ↗ |
| 88 | 2015 | José E. Almeida, Chairman and Chief Executive Officer | 231.5K | — | 2.91M | 4.80M | — | 7.6K | 7.95M | 96.99% | ↗ |
| 89 | 2015 | José E. Almeida Chairman of the Board, Chief Executive Officer and President | 231.5K | — | 2.91M | 4.80M | — | 7.6K | 7.95M | 96.99% | ↗ |
| 90 | 2015 | David P. Scharf Former Corporate Vice President, General Counsel | 668.0K | — | 1.44M | 1.07M | 1.66M | 377.9K | 5.21M | 48.08% | ↗ |
| 91 | 2015 | David P. Scharf, Corporate Vice President, General Counsel and Corporate Secretary | 668.0K | — | 1.44M | 1.07M | 1.66M | 377.9K | 5.21M | 48.08% | ↗ |
| 92 | 2015 | Robert J. Hombach, Former Corporate Vice President and Chief Financial Officer | 386.9K | — | 1.64M | 1.22M | 1.86M | 50.8K | 5.16M | 55.51% | ↗ |
| 93 | 2015 | Ludwig N. Hantson, Former Corporate Vice President and President, BioScience | 527.4K | — | 1.70M | 1.22M | 1.05M | 67.0K | 4.57M | 63.93% | ↗ |
| 94 | 2015 | Jeanne K. Mason, Corporate Vice President, Human Resources | 540.2K | — | 1.03M | 764.8K | 1.44M | 369.0K | 4.14M | 43.22% | ↗ |
| 95 | 2015 | James K. Saccaro, Corporate Vice President and Chief Financial Officer | 622.0K | 250.0K | 913.0K | 917.8K | 834.0K | 75.1K | 3.61M | 50.69% | ↗ |
| 96 | 2015 | James K. Saccaro Corporate Vice President and Chief Financial Officer | 622.0K | 250.0K | 913.0K | 917.8K | 834.0K | 75.1K | 3.61M | 50.69% | ↗ |
| 97 | 2015 | James K. Saccaro Executive Vice President and Chief Financial Officer | 622.0K | 250.0K | 913.0K | 917.8K | 834.0K | 75.1K | 3.61M | 50.69% | ↗ |
| 98 | 2014 | Robert L. Parkinson, Jr., Chairman and Chief Executive Officer | 1.54M | — | 3.58M | 4.54M | 3.17M | 9.5K | 15.30M | 53.07% | ↗ |
| 99 | 2014 | Robert L. Parkinson, Jr., Former Chairman and Chief Executive Officer | 1.54M | — | 3.58M | 4.54M | 3.17M | 2.48M | 15.30M | 53.07% | ↗ |
| 100 | 2014 | Robert J. Hombach, Former Corporate Vice President and Chief Financial Officer | 757.0K | — | 3.89M | 1.19M | 1.05M | 2.66M | 9.54M | 53.21% | ↗ |
| 101 | 2014 | Robert J. Hombach, Corporate Vice President and Chief Financial Officer | 755.0K | — | 3.89M | 1.19M | 1.05M | 57.5K | 9.54M | 53.22% | ↗ |
| 102 | 2014 | David P. Scharf Former Corporate Vice President, General Counsel | 651.4K | — | 2.66M | 1.04M | 800.9K | 508.0K | 5.66M | 65.37% | ↗ |
| 103 | 2014 | David P. Scharf, Corporate Vice President, General Counsel and Corporate Secretary | 651.4K | — | 2.66M | 1.04M | 800.9K | 508.0K | 5.66M | 65.37% | ↗ |
| 104 | 2014 | Jeanne K. Mason, Corporate Vice President, Human Resources | 525.6K | — | 2.43M | 744.5K | 608.9K | 579.1K | 4.89M | 64.93% | ↗ |
| 105 | 2014 | Ludwig N. Hantson, Former Corporate Vice President and President, BioScience | 840.2K | — | 972.6K | 1.19M | 1.37M | 118.3K | 4.49M | 48.16% | ↗ |
| 106 | 2014 | Ludwig N. Hantson, Corporate Vice President and President, BioScience | 833.8K | — | 972.6K | 1.19M | 1.37M | 118.3K | 4.49M | 48.23% | ↗ |
| 107 | 2013 | Robert L. Parkinson, Jr., Former Chairman and Chief Executive Officer | 1.53M | — | 6.84M | 4.79M | 2.70M | 310.9K | 16.16M | 71.96% | ↗ |
| 108 | 2013 | Robert L. Parkinson, Jr., Chairman and Chief Executive Officer | 1.52M | — | 6.84M | 4.79M | 2.70M | 9.2K | 16.16M | 71.97% | ↗ |
| 109 | 2013 | Ludwig N. Hantson, Former Corporate Vice President and President, BioScience | 743.7K | — | 1.10M | 1.43M | 1.00M | 135.3K | 4.41M | 57.28% | ↗ |
| 110 | 2013 | Ludwig N. Hantson, Corporate Vice President and President, BioScience | 742.3K | — | 1.10M | 1.43M | 1.00M | 135.3K | 4.41M | 57.30% | ↗ |
| 111 | 2013 | Robert J. Hombach, Former Corporate Vice President and Chief Financial Officer | 689.9K | — | 877.3K | 1.14M | 890.4K | 799.3K | 4.40M | 45.91% | ↗ |
| 112 | 2013 | Robert J. Hombach, Corporate Vice President and Chief Financial Officer | 687.7K | — | 877.3K | 1.14M | 890.4K | 54.5K | 4.40M | 45.94% | ↗ |
| 113 | 2013 | Robert M. Davis, Corporate Vice President and President, Medical Products | 742.3K | — | 1.10M | 1.43M | 772.5K | 72.9K | 4.21M | 59.94% | ↗ |
| 114 | 2013 | Jean-Luc Butel, Corporate Vice President | 771.2K | — | 1.05M | 1.37M | 918.0K | 66.3K | 4.18M | 58.00% | ↗ |
| 115 | 2012 | Robert L. Parkinson, Jr., Chairman and Chief Executive Officer | 1.45M | — | 6.35M | 3.92M | 4.28M | 9.0K | 17.52M | 58.62% | ↗ |
| 116 | 2012 | Jean-Luc Butel, Corporate Vice President | 649.0K | 1.00M | 5.42M | 3.10M | 1.12M | 25.4K | 11.31M | 75.32% | ↗ |
| 117 | 2012 | Robert M. Davis, Corporate Vice President and President, Medical Products | 692.3K | — | 3.97M | 906.2K | 1.37M | 53.9K | 7.47M | 65.30% | ↗ |
| 118 | 2012 | Ludwig N. Hantson, Corporate Vice President and President, BioScience | 692.3K | — | 3.97M | 906.2K | 1.37M | 102.1K | 7.04M | 69.30% | ↗ |
| 119 | 2012 | Robert J. Hombach, Corporate Vice President and Chief Financial Officer | 609.2K | — | 1.47M | 906.2K | 873.8K | 43.7K | 5.37M | 44.18% | ↗ |
| 120 | 2011 | Robert L. Parkinson, Jr., Chairman and Chief Executive Officer | 1.41M | — | 5.10M | 3.39M | 2.90M | 37.1K | 14.07M | 60.33% | ↗ |
| 121 | 2011 | Ludwig N. Hantson, Corporate Vice President and President, BioScience | 640.8K | — | 1.61M | 863.5K | 904.8K | 74.9K | 4.10M | 60.45% | ↗ |
| 122 | 2011 | Robert M. Davis, Corporate Vice President and President, Medical Products | 642.3K | — | 1.30M | 863.5K | 867.1K | 45.9K | 4.02M | 53.89% | ↗ |
| 123 | 2011 | Robert J. Hombach, Corporate Vice President and Chief Financial Officer | 534.6K | — | 1.15M | 761.9K | 644.2K | 30.0K | 3.85M | 49.65% | ↗ |
| 124 | 2011 | David P. Scharf, Corporate Vice President, General Counsel and Corporate Secretary | 538.5K | — | 918.0K | 609.5K | 644.2K | 28.9K | 2.87M | 53.29% | ↗ |
| 125 | 2010 | Robert L. Parkinson, Jr., Chairman and Chief Executive Officer | 1.37M | — | 4.45M | 2.67M | 1.04M | 147.6K | 11.50M | 61.84% | ↗ |
| 126 | 2010 | Jeanne K. Mason, Corporate Vice President, Human Resources | 385.8K | 558.0K | 1.81M | — | 531.0K | 16.6K | 3.75M | 48.24% | ↗ |
| 127 | 2010 | Ludwig N. Hantson, Corporate Vice President and President, BioScience | 385.8K | 558.0K | 1.81M | 447.8K | 531.0K | 16.6K | 3.75M | 60.19% | ↗ |
| 128 | 2010 | Robert M. Davis, Corporate Vice President and President, Medical Products | 596.9K | — | 1.31M | 655.4K | 518.7K | 80.2K | 3.37M | 58.27% | ↗ |
| 129 | 2010 | Peter J. Arduini, Former Corporate Vice President and President, Medication Delivery | 481.5K | — | 1.09M | — | 285.0K | 258.7K | 3.01M | 36.31% | ↗ |
| 130 | 2010 | Robert J. Hombach, Corporate Vice President, Chief Financial Officer and Treasurer | 388.4K | — | 523.7K | — | 286.7K | 31.5K | 1.89M | 27.75% | ↗ |
| 131 | 2010 | Robert J. Hombach, Corporate Vice President and Chief Financial Officer | 388.4K | — | 523.7K | 183.7K | 286.7K | 31.5K | 1.89M | 37.48% | ↗ |
| 132 | 2009 | Robert L. Parkinson, Jr., Chairman and Chief Executive Officer | 1.34M | — | 4.79M | 2.98M | 2.50M | 233.1K | 14.36M | 54.09% | ↗ |
| 133 | 2009 | Robert L Parkinson, Jr., Chairman and Chief Executive Officer | 1.34M | — | 4.79M | — | 2.50M | 233.1K | 14.36M | 33.32% | ↗ |
| 134 | 2009 | Peter J. Arduini, Former Corporate Vice President and President, Medication Delivery | 576.9K | — | 1.07M | — | 814.3K | 102.9K | 3.43M | 31.07% | ↗ |
| 135 | 2009 | Joy A. Amundson, Corporate Vice President and President, BioScience | 576.9K | — | 1.07M | — | 814.3K | 102.9K | 3.43M | 31.07% | ↗ |
| 136 | 2009 | Robert M. Davis, Corporate Vice President and President, Medical Products | 576.9K | — | 1.07M | 668.1K | 814.3K | 101.0K | 3.34M | 51.91% | ↗ |
| 137 | 2009 | Ludwig N. Hantson, Corporate Vice President and President, BioScience | 576.9K | — | 1.07M | — | 814.3K | 101.0K | 3.34M | 31.92% | ↗ |
| 138 | 2009 | Robert M. Davis, Corporate Vice President, Chief Financial Officer | 576.9K | — | 1.07M | — | 814.3K | 101.0K | 3.34M | 31.92% | ↗ |
| 139 | 2009 | Peter J. Arduini, Corporate Vice President and President, Medication Delivery | 543.5K | — | 978.0K | — | 723.8K | 89.6K | 3.03M | 32.28% | ↗ |
| 140 | 2009 | Susan R. Lichtenstein, Former Corporate Vice President and General Counsel | 385.3K | — | 962.3K | — | 309.0K | 473.5K | 2.80M | 34.33% | ↗ |
| 141 | 2009 | John J. Greisch, Former Corporate Vice President and President, International | 216.1K | — | 1.01M | — | 189.0K | 526.9K | 2.66M | 37.89% | ↗ |
| 142 | 2009 | Bruce McGillivray, Corporate Vice President and President, Renal | 422.6K | — | 562.2K | — | 496.1K | 58.1K | 2.20M | 25.54% | ↗ |
| 143 | 2008 | Robert L Parkinson, Jr., Chairman and Chief Executive Officer | 1.34M | — | 6.08M | — | 2.71M | 212.3K | 14.82M | 41.04% | ↗ |
| 144 | 2008 | Robert L. Parkinson, Jr., Chairman and Chief Executive Officer | 1.34M | — | 6.08M | — | 2.71M | 212.3K | 14.82M | 41.04% | ↗ |
| 145 | 2008 | John J. Greisch, Corporate Vice President and President, International | 613.5K | — | — | — | — | — | 5.11M | 0.00% | ↗ |
| 146 | 2008 | John J. Greisch, Former Corporate Vice President and President, International | 613.5K | — | 2.01M | — | 938.0K | 125.3K | 4.75M | 42.30% | ↗ |
| 147 | 2008 | Joy A. Amundson, Corporate Vice President and President, BioScience | 554.8K | — | 1.28M | — | 866.3K | 109.1K | 3.67M | 34.98% | ↗ |
| 148 | 2008 | Peter J. Arduini, Former Corporate Vice President and President, Medication Delivery | 554.8K | — | 1.28M | — | 866.3K | 109.1K | 3.67M | 34.98% | ↗ |
| 149 | 2008 | Robert M. Davis, Corporate Vice President, Chief Financial Officer | 554.8K | — | 1.28M | — | 866.3K | 90.9K | 3.57M | 35.88% | ↗ |
| 150 | 2008 | Ludwig N. Hantson, Corporate Vice President and President, BioScience | 554.8K | — | 1.28M | — | 866.3K | 90.9K | 3.57M | 35.88% | ↗ |
| 151 | 2008 | Peter J. Arduini, Corporate Vice President and President, Medication Delivery | 526.9K | — | 1.28M | — | 527.7K | 97.0K | 3.22M | 39.78% | ↗ |
| 152 | 2008 | Robert M. Davis, Corporate Vice President and President, Medical Products | 526.9K | — | 1.28M | — | 527.7K | 97.0K | 3.22M | 39.78% | ↗ |
| 153 | 2007 | Robert L Parkinson, Jr., Chairman and Chief Executive Officer | 1.30M | — | 7.60M | — | 3.00M | 153.2K | 19.20M | 39.62% | ↗ |
| 154 | 2007 | John J. Greisch, Former Corporate Vice President and President, International | 595.2K | — | 2.22M | — | 1.09M | 107.7K | 5.28M | 42.13% | ↗ |
| 155 | 2007 | John J. Greisch, Corporate Vice President and President, International | 595.2K | — | — | — | — | — | 5.11M | 0.00% | ↗ |
| 156 | 2007 | Joy A. Amundson, Corporate Vice President and President, BioScience | 523.1K | — | 2.06M | — | 907.4K | 94.1K | 4.67M | 44.18% | ↗ |
| 157 | 2007 | J. Michael Gatling, Corporate Vice President, Global Manufacturing and Supply Chain | 376.2K | — | 1.67M | — | 475.2K | 58.3K | 4.32M | 38.68% | ↗ |
| 158 | 2007 | Peter J. Arduini, Corporate Vice President and President, Medication Delivery | 505.7K | — | 1.97M | — | 692.2K | 86.5K | 4.29M | 45.83% | ↗ |
| 159 | 2007 | Robert M. Davis, Corporate Vice President, Chief Financial Officer | 506.6K | — | 1.85M | — | 793.6K | 58.6K | 4.22M | 43.76% | ↗ |
| 160 | 2006 | Robert L Parkinson, Jr., Chairman and Chief Executive Officer | 1.19M | — | — | — | — | — | 13.58M | 0.00% | ↗ |
| 161 | 2006 | Robert L. Parkinson, Jr., | 1.19M | — | 1.53M | — | 3.00M | 136.2K | 13.58M | 11.24% | ↗ |
| 162 | 2006 | John J. Greisch, Corporate Vice President and President, International | 564.0K | — | — | — | — | — | 3.94M | 0.00% | ↗ |
| 163 | 2006 | Joy A. Amundson, Corporate Vice President and President, BioScience | 508.1K | — | — | — | — | — | 3.46M | 0.00% | ↗ |
| 164 | 2006 | Peter J. Arduini, Corporate Vice President and President, Medication Delivery | 477.1K | — | — | — | — | — | 2.44M | 0.00% | ↗ |
| 165 | 2006 | J. Michael Gatling, Corporate Vice President, Global Manufacturing and Supply Chain | 345.9K | — | 429.7K | — | 403.8K | 39.8K | 2.22M | 19.36% | ↗ |
| 166 | 2006 | Robert M. Davis, Corporate Vice President, Chief Financial Officer | 359.3K | — | — | — | — | — | 1.50M | 0.00% | ↗ |
| 167 | 2005 | Robert L. Parkinson, Jr. Chairman of the Board, President and Chief | 1.13M | 1.94M | 2.80M | — | — | 63.5K | 5.94M | 47.18% | ↗ |
| 168 | 2005 | John J. Greisch Corporate Vice President and Chief Financial Officer | 514.4K | 810.6K | 1.02M | — | — | 27.3K | 2.37M | 42.98% | ↗ |
| 169 | 2005 | Joy A. Amundson Corporate Vice President and President — BioScience | 492.0K | 770.3K | 941.0K | — | — | 20.4K | 2.22M | 42.32% | ↗ |
| 170 | 2005 | Peter J. Arduini Corporate Vice President and President — Medication | 320.2K | 514.5K | 783.6K | — | — | 810.00 | 1.62M | 48.40% | ↗ |
| 171 | 2005 | James E. Utts Corporate Vice President and President — Europe | 484.0K | 462.1K | 470.5K | — | — | 20.0K | 1.44M | 32.75% | ↗ |
| 172 | 2004 | Harry M. Jansen Kraemer, Jr. Former Chairman of the Board and Chief Executive Officer | 535.4K | 578.1K | — | — | — | 4.21M | 5.33M | 0.00% | ↗ |
| 173 | 2004 | Robert L. Parkinson, Jr. Chairman of the Board and Chief Executive Officer | 761.5K | 916.7K | — | 650.0K | — | 7.6K | 1.69M | 38.56% | ↗ |
| 174 | 2004 | Robert L. Parkinson, Jr. Chairman of the Board, President and Chief | 761.5K | 916.7K | — | — | — | 7.6K | 1.69M | 0.00% | ↗ |
| 175 | 2004 | John J. Greisch Corporate Vice President and Chief Financial Officer | 436.2K | 418.7K | 310.6K | — | — | 15.5K | 1.18M | 26.30% | ↗ |
| 176 | 2004 | John J. Greisch Corporate Vice President Chief Financial Officer | 436.2K | 418.7K | 310.6K | 60.0K | — | 15.5K | 1.18M | 31.38% | ↗ |
| 177 | 2004 | James E. Utts Corporate Vice President and President — Europe | 369.8K | 235.4K | 151.6K | — | — | 13.5K | 770.3K | 19.68% | ↗ |
| 178 | 2004 | James E. Utts Corporate Vice President President, Europe | 354.2K | 235.4K | 151.6K | — | — | 13.5K | 754.7K | 20.09% | ↗ |
| 179 | 2004 | David F. Drohan Corporate Vice President President, Medication Delivery | 493.7K | 172.1K | — | — | — | 34.0K | 699.7K | 0.00% | ↗ |
| 180 | 2004 | Carlos del Salto Corporate Vice President President, Intercontinental/Asia | 491.7K | 172.1K | — | — | — | 28.8K | 692.6K | 0.00% | ↗ |
| 181 | 2004 | Joy A. Amundson Corporate Vice President and President — BioScience | 193.8K | 160.0K | 272.9K | — | — | 297.00 | 627.0K | 43.52% | ↗ |
| 182 | 2004 | Peter J. Arduini Corporate Vice President and President — Medication | — | — | — | — | — | — | — | — | ↗ |
| 183 | 2003 | Harry M. Jansen Kraemer, Jr. Former Chairman of the Board and Chief Executive Officer | 925.0K | 647.5K | — | 300.0K | — | 41.6K | 1.61M | 18.59% | ↗ |
| 184 | 2003 | Harry M. Jansen Kraemer, Jr. Chairman of the Board and Chief Executive Officer | 925.0K | 647.5K | — | 300.0K | — | 41.6K | 1.61M | 18.59% | ↗ |
| 185 | 2003 | Alan L. Heller Former Senior Vice President and President-Renal | 625.0K | 140.0K | — | — | — | 555.7K | 1.32M | 0.00% | ↗ |
| 186 | 2003 | David F. Drohan Corporate Vice President President, Medication Delivery | 420.4K | 364.0K | — | 90.0K | — | 23.6K | 808.0K | 11.14% | ↗ |
| 187 | 2003 | David F. Drohan Senior Vice President and President-Medication Delivery | 420.4K | 364.0K | — | 90.0K | — | 23.6K | 808.0K | 11.14% | ↗ |
| 188 | 2003 | Carlos del Salto Corporate Vice President President, Intercontinental/Asia | 445.0K | 279.1K | — | 90.8K | — | 23.4K | 747.5K | 12.14% | ↗ |
| 189 | 2003 | Carlos del Salto Senior Vice President and President-Intercontinental/Asia and Renal | 445.0K | 279.1K | — | 90.8K | — | 23.4K | 747.5K | 12.14% | ↗ |
| 190 | 2003 | Brian P. Anderson Senior Vice President and Chief Financial Officer | 490.0K | 175.6K | — | 74.3K | — | 19.8K | 685.4K | 10.83% | ↗ |
| 191 | 2003 | James E. Utts Corporate Vice President and President — Europe | — | — | — | — | — | — | — | — | ↗ |
| 192 | 2003 | Robert L. Parkinson, Jr. Chairman of the Board and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 193 | 2003 | John J. Greisch Corporate Vice President Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 194 | 2003 | Joy A. Amundson Corporate Vice President and President — BioScience | — | — | — | — | — | — | — | — | ↗ |
| 195 | 2003 | Robert L. Parkinson, Jr. Chairman of the Board, President and Chief | — | — | — | — | — | — | — | — | ↗ |
| 196 | 2003 | John J. Greisch Corporate Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 197 | 2003 | James E. Utts Corporate Vice President President, Europe | — | — | — | — | — | — | — | — | ↗ |
| 198 | 2003 | Peter J. Arduini Corporate Vice President and President — Medication | — | — | — | — | — | — | — | — | ↗ |
| 199 | 2002 | Harry M. Jansen Kraemer, Jr. Chairman of the Board and Chief Executive Officer | 916.3K | 403.0K | — | 375.0K | — | 45.4K | 1.36M | 27.48% | ↗ |
| 200 | 2002 | Harry M. Jansen Kraemer, Jr. Former Chairman of the Board and Chief Executive Officer | 916.3K | 403.0K | — | 375.0K | — | 45.4K | 1.36M | 27.48% | ↗ |
| 201 | 2002 | Alan L. Heller Former Senior Vice President and President-Renal | 620.2K | 164.0K | — | 84.0K | — | 26.8K | 811.0K | 10.36% | ↗ |
| 202 | 2002 | Carlos del Salto Corporate Vice President President, Intercontinental/Asia | 441.2K | 176.0K | — | 99.0K | — | 23.2K | 640.4K | 15.46% | ↗ |
| 203 | 2002 | Carlos del Salto Senior Vice President and President-Intercontinental/Asia and Renal | 441.2K | 176.0K | — | 99.0K | — | 23.2K | 640.4K | 15.46% | ↗ |
| 204 | 2002 | Brian P. Anderson Senior Vice President and Chief Financial Officer | 486.2K | 128.6K | — | 66.0K | — | 23.4K | 638.1K | 10.34% | ↗ |
| 205 | 2002 | David F. Drohan Corporate Vice President President, Medication Delivery | 404.2K | 121.0K | — | 82.5K | — | 22.3K | 547.5K | 15.07% | ↗ |
| 206 | 2002 | David F. Drohan Senior Vice President and President-Medication Delivery | 404.2K | 121.0K | — | 82.5K | — | 22.3K | 547.5K | 15.07% | ↗ |
| 207 | 2002 | Robert L. Parkinson, Jr. Chairman of the Board and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 208 | 2002 | James E. Utts Corporate Vice President President, Europe | — | — | — | — | — | — | — | — | ↗ |
| 209 | 2002 | John J. Greisch Corporate Vice President Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 210 | 2001 | Harry M. Jansen Kraemer, Jr. Chairman of the Board and Chief Executive Officer | 880.0K | 528.0K | — | 600.0K | — | 66.8K | 1.47M | 40.68% | ↗ |
| 211 | 2001 | Alan L. Heller Former Senior Vice President and President-Renal | 600.0K | 240.0K | — | 164.7K | — | 990.00 | 841.0K | 19.58% | ↗ |
| 212 | 2001 | Brian P. Anderson Senior Vice President and Chief Financial Officer | 470.0K | 248.5K | — | 120.0K | — | 23.0K | 741.5K | 16.18% | ↗ |
| 213 | 2001 | Carlos del Salto Senior Vice President and President-Intercontinental/Asia and Renal | 425.0K | 224.0K | — | 108.0K | — | 24.7K | 673.7K | 16.03% | ↗ |
| 214 | 2001 | David F. Drohan Senior Vice President and President-Medication Delivery | 361.5K | 224.0K | — | 105.0K | — | 19.3K | 604.8K | 17.36% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrew Hider | Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director | 3M | male |
| Cynthia Carlisle | Executive Vice President & Chief Human Resources Officer | 2M | female |
| Reazur Rasul | Executive Vice President & Group President of Healthcare Systems and Technologies | 1M | male |
| Joel T. Grade | Advisor | 1M | male |
| David S. Rosenbloom | Executive Vice President & General Counsel | 1M | male |
| Maria Soriano | Group President of Infusion Therapies & Platforms | 1M | female |
| Julie Foster | President of Front Line Care | — | female |
| Kevin Moran | Vice President & Head of Investor Relations | — | male |
| Piero Novello | Senior Vice President & President of Growth and Emerging Markets | — | male |
| Scott Kaplan | Senior Vice President of Quality, Regulatory & Patient Safety | — | male |
| Stacey Eisen | SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation | — | female |
| Adriana Guiry | Senior Vice President of Baxter Growth & Performance System | — | female |
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2022-11-30 | 2023-07-26 | Dan Sullivan | AK | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-04-14 | 2021-05-02 | David Perdue | — | Joint | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2017-09-22 | 2017-12-06 | David Perdue | — | Joint | Sale (Partial) | $15,001 - $50,000 | ↗ |
| 2017-09-08 | 2017-12-06 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2017-04-26 | 2017-05-05 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2017-03-02 | 2017-03-31 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2017-02-13 | 2018-07-05 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2017-02-08 | 2018-07-05 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2016-11-08 | 2016-12-06 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2016-11-07 | 2016-12-06 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2016-10-12 | 2016-11-02 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2016-08-30 | 2016-09-01 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2016-08-26 | 2016-09-01 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2016-08-25 | 2016-09-01 | David Perdue | — | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2015-12-15 | 2016-08-12 | David Perdue | — | Joint | Purchase | $100,001 - $250,000 | ↗ |
| 2015-08-28 | 2016-08-12 | David Perdue | — | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2015-08-27 | 2016-08-12 | David Perdue | — | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2015-08-26 | 2015-09-08 | David Perdue | — | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2015-08-25 | 2016-08-12 | David Perdue | — | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2015-08-24 | 2016-08-12 | David Perdue | — | Joint | Purchase | $1,001 - $15,000 | ↗ |
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-23 | 2026-04-10 | Michael McCaul | TX10 | Spouse | Purchase | $15,001 - $50,000 | ↗ |
| 2026-01-13 | 2026-02-12 | Michael McCaul | TX10 | Spouse | Purchase | $50,001 - $100,000 | ↗ |
| 2025-10-31 | 2025-11-24 | Lisa McClain | MI09 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2025-10-30 | 2025-11-24 | Lisa McClain | MI09 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2025-10-30 | 2025-11-24 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2025-09-29 | 2025-10-03 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-09-25 | 2025-10-22 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2025-09-05 | 2025-10-03 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-09-03 | 2025-10-03 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-08-26 | 2025-09-12 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-12 | 2025-09-12 | Ro Khanna | CA17 | Spouse | Sale | $1,000 - $15,000 | ↗ |
| 2025-08-04 | 2025-09-12 | Ro Khanna | CA17 | Spouse | Purchase | $1,000 - $15,000 | ↗ |
| 2025-08-04 | 2025-09-15 | Lisa McClain | MI09 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2025-07-22 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2025-05-15 | 2025-06-10 | Rob Bresnahan | PA08 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-07-09 | 2024-08-06 | Earl Blumenauer | OR03 | Spouse | Purchase | $15,001 - $50,000 | ↗ |
| 2024-01-08 | 2024-02-05 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-10-31 | 2023-11-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-10-20 | 2023-11-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-17 | 2023-11-08 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BAX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
